Seton Hall University

eRepository @ Seton Hall
Seton Hall University Dissertations and Theses
(ETDs)

Seton Hall University Dissertations and Theses

Fall 8-20-2014

Submonomer Synthesis and Structure-activity
Relationship Studies of Azapeptide Inhibitors of
the Insulin Receptor Tyrosine Kinase
Lathamol A. Kurian
lathamol.kurian@student.shu.edu

Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry Commons, and the
Medicinal Chemistry and Pharmaceutics Commons
Recommended Citation
Kurian, Lathamol A., "Submonomer Synthesis and Structure-activity Relationship Studies of Azapeptide Inhibitors of the Insulin
Receptor Tyrosine Kinase" (2014). Seton Hall University Dissertations and Theses (ETDs). 1991.
https://scholarship.shu.edu/dissertations/1991

CHAPTER 1. AZAPEPTIDES: AN OVERVIEW OF THEIR
SYNTHESIS, STRUCTURE AND APPLICATIONS IN MEDICINAL
CHEMISTRY

1.1 ABSTRACT

Azapeptides are a class of peptide mimics (peptidomimetics), which have served as
valuable tools for the development of peptide-based therapeutics. The biological activity of
azapeptides has been correlated to its primary sequence and most importantly their ability to
pre-organize bio-active secondary structures. Therefore, understanding the influence of
azapeptide sequence and conformation on biological activity is significant for the
development of selective and potent therapeutic agents. As determined by NMR, CD and IR
spectroscopy, and X-ray crystallography in addition to computational analyses, the insertion
of an aza-amino acid residue within a peptide sequence has been shown to pre-organize the
azapeptide backbone into well folded β-turn conformations. Considering the relevance of turn
structures in biologically active peptide sequences such as those belonging to the Growth
Hormone Releasing Peptides (GHRPs), Oxytocin and the Leutinizing Hormone Releasing
Hormone (LH-RH), azapeptide derivatives have produced enhanced peptide activity
facilitating the translation of lead ligands into therapeutic agents. For example, Goserelin, an
aza-Gly peptide analog has received FDA approval in 1989 for the treatment of prostate and
breast cancers. Therefore, azapeptides have been adopted for the development of peptidebased drugs. At the heart of their fruitful applications are robust chemical synthesis methods
which produce azapeptides by solution phase or solid phase peptide chemistry. The solution
phase approach requires work-up and purification procedures following each synthetic step
making the production of lengthy and more complex sequences difficult to accomplish.
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Alternatively, the solid phase synthesis of azapeptides by-passes the laborious solution phase
approach by employing a solid support. The first successful solid phase azapeptide syntheses
involved the pre-requisite formation of the aza-amino acid building blocks in solution prior to
azapeptide synthesis on solid phase. The submonomer approach introduced in 2009
circumvents any solution phase synthesis and builds azapeptides directly on solid phase. This
has led to the rapid production of structurally diverse azapeptide libraries for structureactivity relationship studies with receptor targets. This chapter will highlight the role of
azapeptides in biology and medicine by underscoring important contributions in synthesis
and structural analyses that has enabled their widespread applications in medicinal chemistry.
1.2 INTRODUCTION
Naturally occurring peptide sequences have been isolated and synthesized for usage in
biology, medicinal chemistry and pharmaceutical research. In spite of their potential, peptides
are limited in their applications due to their poor stabilities in biological media, limited tissue
penetration for biological activity and promiscuous binding to target receptors which restricts
selectivity and potency. In an effort to mitigate these limitations, peptidomimetics have been
designed to mimic naturally occurring peptides in attempts to retain the main biological
function of the native sequences while enhancing their therapeutic efficacy. Many structural
modifications have been incorporated within bio-active peptide sequences with the goal of
producing peptide-based drugs.1-3 Among these modifications, azapeptides are a class of
peptide mimics which substitutes the -carbon for a nitrogen atom in one or more amino acid
producing aza-residues (Figure 1.1).4
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Figure 1.1. Comparison of peptide and azapeptide primary structure.
This single atom change introduces a semicarbazide into the peptide backbone which
causes profound effects on configuration and structure. Replacement of an -carbon for a
nitrogen atom within the aza-residue furnishes a configurationally labile center, rapidly
inverting in between two trigonal pyramidal structures. Moreover, the introduction of a N,N’diacylhydrazine and urea moiety within the peptide backbone, constrains the φ and ψ dihedral
angles producing some types of β-turn conformations as proven by CD, NMR spectroscopy,
X-Ray crystallography and computational analyses.5
Thus, azapeptides have served to improve the structure-activity profiles of peptides by
stabilizing bio-active turns which favor bioavailability, metabolic stability, receptor binding
affinity and selectivity.4 Their fruitful applications are based on robust and efficient synthetic
methods that have produced azapeptides by either solution phase or solid phase peptide
synthesis. The submonomer method for azapeptide synthesis has been especially productive
and has led to the generation of structurally diverse azapeptides for exploring the influence of
structure on biological activity with receptor targets.6
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1.3 SYNTHESIS

Azapeptide synthesis is a combination of hydrazine and peptide chemistry. Azapeptides
have been historically prepared by either activation of the hydrazine moiety or by activation
of the peptide N-terminus. Following activation, a coupling step attaches the aza-amino acid
building block to the peptide sequence. At this stage, conventional peptide synthesis is
continued until the desired azapeptide has been produced. This strategy has been adopted in
solution and on solid phase, necessitating laborious steps in the production of the aza-amino
acid building blocks and in the synthesis of the coveted azapeptides. The submonomer
approach has been developed to circumvent any solution phase chemistry by building the
azapeptide directly on solid phase. Thus, a combination of in-solution and solid phase
techniques have been crafted for making azapeptides in order to explore their structureactivity relationships.
1.3.1

ACTIVATION AND COUPLING OF AZA-AMINO ACIDS

The N-terminus of the growing peptide bound to a solid support has been activated
with carbonyl donors, including bis-(2,4-dinitrophenyl)7,8 carbonate and carbonyldiimidazole
(CDI)9-12, bis(pentafluorophenyl) carbonate13-16, triphosgene17-19, phosgene20-24 to produce
reactive isocyanates, or equivalent carbamoyl halides or active carbamates prior to coupling
with a suitably protected hydrazide (Scheme 1.1, Peptide N-terminus Activation). The
major drawback of this method is the intermolecular nucleophilic attack at the activated
isocyanate by the secondary amide nitrogen leading to the formation of the hydantoin
byproduct which prematurely terminates azapeptide synthesis. Although reversible amide
bond protecting groups have been introduced to prevent hydantoin formation, these methods
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require additional protection and deprotection steps lengthening the synthetic procedures.8
Conversely, activated carbazate intermediates have been prepared by hydrazine activation
with similar carbonyl donors10-12,15-24 and coupled to peptide bound resin to manufacture the
azapeptide on solid phase (Scheme 1.1 Hydrazine Activation).

Scheme 1.1. Peptide N-terminus and hydrazine activation for the synthesis of azapeptides.7-24
1.3.2

SYNTHESIS OF AZAPEPTIDES USING N-FMOC N’-ALKYL CARBAZATES

This hydrazine activation method was one of the first efficient strategies for scanning
the importance and location of turn structures by the incorporation of aza-amino acids within
bio-active peptide sequences.11 The methodology (Scheme 1.2), aptly named, aza-amino acid
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scanning, features the insertion of an N-Fmoc N’-alkyl hydrazine within conventional Fmocbased solid phase peptide synthesis to procure the desired azapeptide for structure-activity
relationship studies. The aza-amino acid monomer is produced in solution, by reductive
amination of Fmoc carbazates. This alkylation step is followed by activation with phosgene
which couples the Fmoc carbazic acid chloride intermediate onto the peptide bound resin.
Fmoc deprotection, chain elongation and cleavage complete the synthesis of the azapeptide.
This methodology was used for the generation of azapeptide analogs of the melanocortin
receptor agonist, the growth hormone releasing peptide (GHRP-6) and the calcitonin generelated peptide antagonist for exploring the effect of azapeptide structure on biological
activity.23-25 In spite of its widespread utility, this methodology suffers from the prerequisite
formation of the aza amino acid monomers by a reductive amination procedure which limits
side chain diversity. To circumvent this limitation, submonomer synthesis was developed to
enable the synthesis of structurally diverse azapeptides for medicinal chemistry applications.

1.11

1.13
1.12

1.14
Aza amino acid scanning

Scheme 1.2. Azapeptide synthesis and aza-amino acid scanning using N-Fmoc carbazates.23
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1.3.3

SUBMONOMER AZAPEPTIDE SYNTHESIS

The submonomer approach for azapeptide synthesis has effectively extended the
scope of side chain diverse azapeptides for structure-activity relationship (SAR) studies with
receptor targets.6,26 This methodology consists of a simple 3-step procedure inserted within
conventional Fmoc-based solid-phase peptide synthesis (SPPS) (Scheme 1.3). These include:
a) hydrazone activation with 4-nitrophenylchloroformate to generate the activated carbazate
intermediate and coupling onto support-bound peptide to generate the N-terminus
semicarbazone. The activation and coupling step is followed by, b) regioselective alkylation
of the semicarbazone to introduce the putative aza-side chain. Finally, c) chemoselective
deprotection of the N-terminal semicarbazone liberates the semicarbazide for continuation of
SPPS until the desired azapeptide has been made.

1.17
1.15

1.18

1.16

1.20

1.21

1.22

Scheme 1.3. Submonomer solid phase azapeptide synthesis method.6,26
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1.19

1.23

Moreover, the submonomer method has furnished azapeptides with un-natural side
chains that were applicable to further diversification yielding new azapeptides. For example,
aza-propargylglycine was effectively prepared for 1,3-dipolar cycloadditions with aryl azides
to

generate

a

seven

compound

library

of

[aza-1,2,3-triazole-3-alanine4]GHRP-6

azapeptides.27 Aza-arylglycine residues have also been prepared by a copper-catalyzed monoarylation procedure during the submonomer azapeptide synthesis.28 Aza-arylglycine
derivatives may form a new class of potent Vancomycin analogs that may be useful in
overcoming growing bacterial resistance upon antibiotic treatment. In a related application,
Sonogashira coupling reactions were optimized by submonomer azapeptide synthesis for
introduction of aza-aryl substituents that cyclized into N-amino-imidazolin-2-ones, forming a
new class of Phe and Trp mimics.29 The copper catalyzed coupling reaction of azapropargylglycine residues with Mannich reagents also proved fruitful in the generation of
rigid Lys mimics.30 These novel aza-residues may prove to be useful substrates for exploring
the influence of ionic azapeptide structure on biological activity.
The submonomer synthesis method has greatly influenced the production of azapeptides.
It has effectively abolished the need for solution phase synthesis of the N-protected N’-alkyl
hydrazides, as well as associated issues with hydantoin by-product formation. Consequently,
the submonomer synthesis has significantly elaborated azapeptide structure and functional
diversity. Regio-selective modifications of semicarbazone peptide on solid phase has
generated novel N-alkylated and N-arylated aza-residues useful for SAR studies.
Submonomer azapeptide synthesis is thus the present day method of choice for making
azapeptides.
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1.4 CONFORMATIONAL PROPERTIES

Stabilization of a particular conformational feature within biologically active peptides
by introducing geometrical constraints may be vital for establishing therapeutic activity. In
azapeptides, replacing a Cα by a Nα generates a hydrazine and a urea constituent, which
restricts the bond rotation about the -CO-NH-N-CONH- peptide backbone. This
conformational restraint may be characterized by the azapeptide torsion angles ϕ (phi) and ψ
(psi).31 In principle, ϕ and ψ can have any values in between -180º and +180º, but many
values are prohibited by steric interference and stereoelectronic effects. The spacial
arrangement of the peptide backbone ϕ and ψ dihedral angles define its secondary structure.
The most prominent secondary structure found within azapeptides are β-turn conformations
(Figure 1.2).

Figure 1.2. Azapeptide β-turn conformation defined by its ϕ and ψ dihedral angles.31
The β-turn is the simplest peptide secondary structure which involves 4 amino acid
residues, with the carbonyl oxygen of the first residue at the i position forming an
intramolecular hydrogen bond (H-bond) with the amino group at the fourth (i+3) position.
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These types of structural motifs often contain glycine and proline residues that stabilize the
turn conformation. Glycine is small and flexible, readily facilitating turn geometries, whereas
proline is a rigid cyclic amino acid which assumes the cis configuration and locks the peptide
backbone into a turn conformation. Proline and glycine have been found at the i+1 and i+2
positions, respectively, of β-turn conformations. Their influence on the ϕ and ψ dihedral
angles favors different types of -turn conformations (Figure 1.3).32,33

Figure 1.3. Structures of naturally occurring β-turn types in peptides and proteins.32,33
Several model systems have been developed to understand the conformational
properties of azapeptides. The most interesting structural variation is associated with the
hydrazine moiety. The energy minimized geometry of the aza-amino acid residue is
influenced by the conformational preferences of the N,N’-diacylhydrazine and urea
components found within the azapeptide. For example, the conformations of hydrazine and
its 1,2-diformyl derivatives, which resemble the aza-amino acid residues, were investigated
by quantum mechanical computational studies.34-38 Ab initio molecular orbital calculations
showed that N,N’-diacylhydrazines adopted non-planar structures in which the nitrogen lone
pairs were found to be perpendicular to one another in the energy minimum conformation.
Moreover, substituted N,N’-diacylhydrazines were found to be configurationally labile,
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interconverting in between two mirror image nitrogen pyramids passing through a planar
structure. Depending on the alkyl substitution pattern of N,N’-diacylhydrazines, a particular
chiral nitrogen pyramid may be preferred at room temperature.37
Insertion of N,N’-diformylhydrazines within peptide sequences results in azapeptides
with torsion angles around 90° for ϕ and about 180° or 0° for ψ.31 These values correspond to
some major types of β-turn secondary structures (Table 1.1). Thus, the aza-amino acid
residues found within azapeptides pre-organizes-turn secondary structures by a
combination of stereoelectronic and structural effects. The N,N’-diacylhydrazine nitrogen
lone pairs exhibit repulsive electrostatic interactions which bends the azapeptide backbone
into an energy minimum turn conformation. Moreover, the rigid urea functions to lock the
turn conformation into a privileged -turn secondary structure.
ϕ

ψ

Table 1.1. Backbone torsion angles for different types of β-turns found within azapeptides.
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A variety of computational, crystallographic and spectroscopic approaches have been
used to investigate azapeptide conformational properties.39-54 The conformations of model
azapeptides containing proline residues have been examined.43,44,46,48,50,53,54 A combination of
the aza-amino acid and proline appeared to be a strong β–turn–inducing motif. Since proline
is known to stabilize β–turn structures, it is uncertain about the contribution of the aza-amino
acid group in such combinations. Theoretical studies on model azapeptide sequences such as,
Ac-azaXaa-NH2 (Xaa = Gly, Ala, Leu) showed that unlike naturally occurring amino acid
residues, azapeptides preferred dihedral angles ϕ = ± 90 ± 30°, ψ = 0 or ±180 ± 30°. The
dihedral angle (ϕ = ± 90 ± 30°, ψ = 0 ± 30°) appeared to correspond to the β–turn
conformation.41 Ab initio calculations coupled to NMR spectroscopy have indicated that the
preferred backbone geometries of azapeptides are similar, regardless of the side–chain
functional groups on the aza-amino acid residue.41 Therefore, the conformational properties
of azapeptides is contingent on the semicarbazide group, which pre-organizes the peptide
backbone into a -turn type conformation. X-ray crystallographic analyses have been
performed on simple azapeptides.47-50,53 The majority of the azapeptides for which the X-ray
data is available, contain proline or aza-proline residues, which may favor turn conformations
and thereby influence the conformational properties of the aza-amino acid residue.
Spectroscopic techniques such as, FT-IR, NMR and CD spectroscopy have also been used for
the structural analyses. FT-IR provides the amide N-H stretching band region (3200 – 3500
cm-1) which is used to distinguish the free amide protons (3400 – 3500 cm-1) from the ones
involved in hydrogen bonding (3200 – 3400 cm-1).41 For example, the FT-IR spectrum of
Boc-Ala-Phe-azaLeu-Ala-OMe in CCl4 produced amide stretching bands at 3440, 3380, and
3320 cm-1. The presence of the band at 3320 and 3380 cm-1 supported the β-turn geometry,
which was also validated by the NMR studies. The carbonyl C=O stretching band region
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(1580 – 1720 cm-1) may also provide evidence of the carbonyl groups involved in hydrogen
bonds. NMR spectroscopy has also been used to study the conformation of smaller model
azapeptides in solution.41,42,44,47,54 Distances between protons have been measured by
studying through space transfer of magnetization by Nuclear Overhauser Effect (NOE)
spectroscopy, to distinguish the aza-proline amide cis- from the trans-isomers. Hydrogen
bonding interactions of the amide protons have also been observed by studying changes in
chemical shift with variation in solvent and temperature. For example, the amide proton of
Ala4 in Boc-Ala-Phe-azaLeu-Ala-OMe was undisturbed by the switch from CDCl3 to
DMSO-d6, indicative of its involvement in an intramolecular hydrogen bonding.41 2D
NOESY experiments in CDCl3 indicated that the amide proton of azaLeu3 exhibited strong
and medium NOE correlations with the α-proton of Phe2 and the amide proton of Ala4,
suggesting a type II β-turn. A weak NOE correlation in between the amide protons of Phe2
and aza-Leu3 indicated that a type I β-turn was likely in equilibrium with the type II
conformer (Figure 1.4).41

Figure 1.4. NOE correlations found within Boc-Ala-Phe-azaLeu-Ala-OMe.41
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Circular Dichorism spectroscopy has also been used to study the structural characteristics of
azapeptides.6 Azapeptide analogs which are less soluble in organic solvents can be assessed
by CD spectroscopy in water and physiological buffer. For example, insertion of aza-Phe4
within GHRP-6 caused a change in the CD signature of the native GHRP-6 sequence from a
random coil to that of a β-turn for the azapeptide. The characteristic CD bands for-turns are
characterized by negative maximum values located at around 190 and 230 nm and a positive
maximum band near 215 nm.55,56
1.5 MEDICINAL CHEMISTRY APPLICATIONS

Azapeptides have been shown to enhance the biological activity of the parent peptide by
facilitating tissue absorption, transport and distribution, improving enzyme or receptor
binding, and metabolic stability. Taken together, these attributes have led to the successful
medicinal chemistry applications of azapeptides.4 For example, azapeptides have resisted
proteolytic degradation by proteases11,22, enhanced binding affinity and selectivity towards
receptor targets6,25 in addition to demonstrating favorable pharmacodynamics which has led
to the FDA approval of the first azapeptide drug, Goserelin, for the treatment of prostate and
breast cancers.57 Thus, azapeptides have proven to be useful tools for the design of drug
candidates for applications in medicinal chemistry.
1.5.1

AZAPEPTIDES AS RECEPTOR AGONISTS AND ANTAGONISTS

Azapeptides have been designed and applied to regulate protein function in SAR
studies that has led to important medicinal chemistry applications. The first azapeptide was
designed and synthesized in 1963, as a modified angiotensin II derivative, [azaVal3]angiotensin II (bovine) [Asp-Arg-azaVal-Tyr-Val-His-Pro-Phe], which reduced activity and
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exhibited longer duration of action relative to its parent peptide in a standard blood pressure
assay.58 Azapeptide analogs of the peptide hormone oxytocin, used therapeutically to induce
labor contractions have been made with varying degrees of biological activities. For example,
the azaAsn5-oxytocin was inactive when tested within rat uterus, while azaGly9-oxytocin held
1.5-fold greater activity than the parent peptide.59,60 Azapeptide analogues of the leutinizing
hormone-releasing hormone (LH-RH) [Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2],
responsible for the release of the leutinizing hormone (LH) and the follicle-stimulating
hormone (FSH), have been prepared and demonstrated a 100-fold enhancement relative to the
parent hormone.61 An azapeptide analog, [D-Ser(t-Bu)6, azaGly10]-LH-RH (Zoladex®,
Goserelin acetate, AstraZeneca Inc.) was approved for clinical use of prostate and breast
cancer.57
Azapeptide regulators of the integrin receptors αIIbβ3 and αvβ3 have been applied in
platelet aggregation and pathologies such as osteoporosis, restenosis, angiogenesis and acute
renal failure.21 The native peptide ligand, Arg-Gly-Asp (RGD), was replaced by six
azapeptides substituting glycine by aza-glycine, aza-alanine or aza-sarcosine and Arg with 4cis-guanidinocyclohexanecarboxylic acid and δ-guanidinovaleric acid. SAR studies led to the
development of aminopyridine 154 (Figure 1.5, 1.24) which exhibited high selectivity and
nanomolar binding affinity for the αvβ3 receptor.
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1.24

Figure 1.5. Lead RGD azapeptide mimic, 1.24, as a selective and potent antagonist of the
αvβ3 receptor.
Azapeptide analogs of the Growth Hormone Releasing Peptides (GHRP-6), were also
developed to improve binding selectivity and affinity to the Cluster of Differentiation 36
(CD36) scavenger receptor implicated in atherosclerosis, angiogenesis and in age-related
macular degeneration.6,62 The native hormone, GHRP-6 exhibits dual binding activity for the
Growth Hormone Secretagogue Receptor 1a (GHS-R1a) and the CD36 scavenger receptor.
The pharmacophoric region of the growth hormone secretagogue GHRP-6, D-Trp-Ala-Trp,
was systematically replaced by aza-amino acids residues to explore the importance of a turn
conformation and side chain binding interactions on CD36 binding affinity and selectivity.
An aza-Phe4 analog caused a 1000-fold improvement in selectivity for the CD36 receptor
while reducing binding with GHS-R1a. Thus, azapeptide ligands of GHRP-6 may be useful
leads in the development of selective forms of anti-atherosclerotic and anti-angiogenic
treatments.

The melanocortin receptor (MCR) agonist, Ac-His-D-Phe-Arg-Trp-NH2, has been
implicated in the regulation of skin pigmentation, steroidogenesis, obesity, energy
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homeostasis, and exocrine gland function. Its widespread biological activity is stimulated by
its promiscuous binding to MCR subtypes mMC1R, mMC3R, mMC4R, and mMC5R. Thus,
potent and selective ligands may lead to the regulation of specific metabolic signaling
pathways. Towards this goal, aza-residues, for D-Phe and Arg, have been developed for
stabilizing the putative bio-active -turn found within the native sequence. These
modifications caused a decrease in binding to the mMC1R and mMC4R, while substitution of
Trp with aza-Nal-1, aza-Nal-2, and aza-Bip yielded analogs which displayed activity similar
to the native sequence.25

Azapeptide analogs of the calcitonin gene-related peptide (CGRP) were developed to
improve the inhibitory activity of this physiologically important peptide implicated in noninsulin-dependent diabetes mellitus, migraine headache, pain, and inflammation.63 The
insertion of aza-Gly33 within [D31,G33,P34,F35]CGRP27-37 led a 10-fold increase in inhibitory
activity when compared to CGRP27-37. Thus, azapeptides have displayed an exquisite ability
to modulate target receptor function with an affinity and selectivity that is absent in their
naturally occurring counterparts. These favorable effects have led to the development of lead
azapeptide ligands that are currently in the pipeline for drug design and development.
1.5.2

AZAPEPTIDES AS PROTEASE INHIBITORS

Azapeptide inhibitors of serine and cysteine proteases have also been developed for
medicinal chemistry applications. Interestingly, azapeptides possessing electrophilic azaresidues at the P1 position have been designed and developed as selective irreversible
inhibitors of cysteine proteases.64-72 A requirement for selective inhibition of cysteine over
serine proteases is related to the incorporation of leaving groups, such as p-nitrophenolate
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ion, which react preferentially with the active site cysteine thiol relative to the serine
hydroxyl group. Therefore, activated esters of azapeptides N-Ac-Phe-azaGly-OPh have been
prepared for the rapid and effective inhibition of cysteine proteases (>11,000 M-l s-l).64 More
recently, azapeptides with reactive site halomethyl ketones, Michael acceptors and epoxides
have all served as potent covalent inhibitors of cysteine proteases, such as the those
belonging to the therapeutically relevant caspase family of cell death effector proteins
(Figure 1.6).66,68-70,72 These substrates have been developed for therapeutic applications and
also as biological probes for elucidating the mechanisms and kinetics associated with enzyme
activity.73,74

Figure 1.6. Representative azapeptide covalent inhibitors of cysteine proteases. Epoxide
inhibitor, 1.25. Acyloxymethylketone inhibitors, 1.26, Nitrile inhibitor, 1.27.64-72
Active site serine protease azapeptide inhibitors, such as the thrombin serine
proteases, which plays a key role in blood coagulation, have also been developed. The
ketoargininamide Boc-azaPhe-trans-Chx-Arg-CONH(s-PhEt) sequence was found to be the
most potent inhibitor in this series.75 A cyclic azapeptide inhibitor of HCV NS3 serine
proteases has also been developed as a potential anti-viral agent. The lead macrocyclic
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tripeptide, BILN 2061, displayed potent inhibition of the HCV NS3 serine protease (Figure
1.7).22 Furthermore, NMR spectroscopy and molecular modeling indicated that a bio-active

-turn conformation for the lead analog BILN 2061 contributed to tight binding to the active
site of the HCV NS3 protease.22 Therefore, introduction of aza-amino acid residues along the
backbone of bio-active peptides have provided enhanced protease inhibitor efficacy. These
results are not only important for therapeutic applications, but also improve peptide metabolic
stability for longer duration of action in biological media. Moreover, azapeptides own the
ability to pre-organize the biologically active -turn responsible for potent and selective
regulation of enzyme targets.

Figure 1.7. Macrocyclic azapeptide inhibitor, BILN 2061, of HCV NS3 serine protease.22
1.6 CONCLUSIONS

Azapeptides are a special class of peptide mimics which introduce a change in
configuration and a pre-organization of the peptide backbone -turn structure found within
native sequences. These structural changes are due to a combination of stereoelectronic and
structural effects. The N,N’-diacylhydrazine moiety bends the peptide backbone into a turn
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geometry due to the repulsive electrostatic effects of the nitrogen lone pairs and the rigid urea
stabilizing the turn conformation. The conformational preferences of azapeptides have been
observed by molecular modeling, spectroscopic and crystallographic studies. The preorganized azapeptide -turn structure has translated into enhanced biological activity in lead
peptide sequences. In these cases, aza-amino acid scanning effected by the submonomer
approach allows for the systematic incorporation of aza-amino acid residues along the peptide
backbone for exploring the location and importance of a turn geometry on peptide activity.
This methodology has enabled the rapid production of structurally diverse azapeptides for
SAR studies. This has led to the development of lead azapeptide ligands as potent and
selective regulators of receptor signaling activity in-vitro and in-vivo. Moreover, azapeptides
have also been designed and developed as antagonists of enzyme activity. This has led to a
production of azapeptide inhibitors of serine and cysteine proteases with an increase in
metabolic stability which produces a longer duration of action. These substrates are also
important for the better understanding of the mechanisms and kinetics of these important
enzymes. Thus, azapeptides are vital tools in biological applications related to the
development of potent and selective peptide-based drugs.
1.7 THESIS OBJECTIVES
In this thesis, the submonomer method is applied and optimized for the production of a
small library (7) of azapeptide inhibitors of the Insulin Receptor Tyrosine Kinase (IRTK)
domain. In cancer, the IRTK is overexpressed at the cell surface where it signals metabolic
activity, protein expression and cell proliferation without regulation, that are all hallmarks of
tumorigenesis.76 Thus, potent and selective inhibitors of the IRTK may for the basis of
effective anti-cancer agents. Towards this goal, a short pentapeptide, Ac-DIYET-NH2,
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derived from the activation loop of the IRTK has shown inhibitory activity towards IRTK
autophosphorylation, albeit at high doses which limits therapeutic efficacy (80% at 4 mM).77
Interestingly, molecular docking of the lead peptide bound to the active site of the IRTK
indicated a folded peptide structure, reminiscent of a -turn conformation. In order to
evaluate whether the -turn structure contributed to peptide activity, a series of Ac-DIYETNH2, azapeptides were designed to effect potent and specific inhibition of the IRTK.
In chapter 2 of this thesis, the submonomer azapeptide synthesis method is described for
the production of azapeptides designed to inhibit IRTK autophosphorylation. Azapeptide
modifications within the IYE pharmacophoric region are anticipated to stabilize the
biologically active turn conformation. Moreover, the submonomer approach also enables the
generation of novel aza-amino acid residues which contain un-natural side chains that may
improve binding affinity and inhibitory activity. For example, a novel aza-DOPA analog is
expected to be a more potent inhibitor of IRTK autophosphorylation due to the multiple
hydroxyl groups at the aza-position. This is an important requirement, as Tyr residues have
been attributed as the active site residues for IRTK phosphorylation which contributes to
receptor signaling activity.
In Chapter 3, a conformational analysis is anticipated to provide insight into our SAR
study. A molecular IRTK docking study of a lead azapeptide ligand, Ac-DIazaYET-NH2,
compared to its native sequence is expected to provide a theoretical model describing the
presence and location of the putative peptide -turn. CD and NMR spectroscopy will be used
to validate the secondary structures of the azapeptides synthesized in this study.
In order to investigate the relationship between the conformational properties observed
for the azapeptides and their biological activities, an IRTK inhibition assay is described in
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Chapter 4. A western blot experiment is used to determine the propensity in which the
azapeptides inhibit IRTK autophosphorylation in the presence of ATP. These studies are not
only significant for our SAR studies, but also in the development of new azapeptide
inhibitors of the IRTK. These may prove to be useful leads in the development of peptidebased anti-cancer drugs and also as valuable substrates for elucidating the mechanisms and
kinetics of these important enzymes.
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CHAPTER 2. SOLID PHASE SUBMONOMER SYNTHESIS OF
AZAPEPTIDE ANALOGS OF THE Ac-DIYET-NH2 SEQUENCE

2.1

ABSTRACT
A small library (7) of azapeptide derivatives of the Ac-DIYET-NH2, 2.28, sequence

has been prepared by submonomer azapeptide synthesis in an effort to explore the importance
of a turn conformation on peptide activity. The synthetic pentapeptide, Ac-DIYET-NH2, 2.28,
was found to inhibit the autophosphorylation of the insulin receptor tyrosine kinase (IRTK)
domain to about 80% at 4 mM, making it a potential lead in the development of novel
peptide-based anti-cancer drugs. The submonomer method for making azapeptide derivatives
of the Ac-DIYET-NH2, 2.28, sequence featured a modified three step procedure, (a)
activation and coupling, (b) alkylation and (c) deprotection, inserted within conventional
Fmoc-based solid phase peptide synthesis. Aza-amino acid residues were built within the IYE
pharmacophoric region of Ac-DIYET-NH2, 2.28, including new aza-Ile and aza-DOPA
residues. Azapeptides were prepared in sufficient isolated yields (36% - 55%) and purities >
95% for structure activity relationship (SAR) studies (Chapters 3 and 4).

2.2

INTRODUCTION
Azapeptides are a special class of peptide mimics formed by the incorporation of aza-

amino acid monomers within a peptide sequence.1 The site-specific insertion of aza-amino
acid residues along a peptide sequence (i.e. aza-amino acid scanning) has been used to
identify the importance and location of -turn-conformations on peptide biological activity.2
Thus, azapeptides have enhanced binding affinity and selectivity against biological targets3
and have improved pharmacokinetic properties for the translation of biologically active
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peptides into azapeptide drugs.4 Enabling their utility in biological and medicinal applications
are more than 50 years of method development. These have involved a combination of
solution phase hydrazine and peptide chemistry5 and evolved into the present day
submonomer approach for azapeptide synthesis.6
Historically, azapeptide synthesis has necessitated the pre-requisite formation of
activated hydrazine precursors in solution prior to their incorporation within a peptide
sequence on solid phase. Among the most common aza-amino acid builidng blocks prepared
for the solid phase synthesis of azapeptides are the N-Fmoc protected N′-alkyl hydrazine7 and
N-Boc aza-dipeptide fragments8, as well as N-Fmoc-9 and N-2-(3,5-dimethoxyphenyl)propan2-yloxy-carbonyl (Ddz)10-protected aza-amino acid chlorides. The Fmoc/Ddz-strategies
(Scheme 2.1) have been especially useful in producing small librairies of azapeptides for
exploring SAR studies with receptor targets.9,10 These methods required the solution phase
preparation of the N-Fmoc or N-Ddz-protected N′-substituted carbazates, 2.1. These azaamino acid building blocks were prepared by reductive amination, followed by a phosgene
treatment which generated the activated aza-amino acid chloride, 2.2, for coupling to the
resin bound peptide, 2.3. In spite of their utility in aza-amino scanning, these methods have
limited widespread applicability due to the difficulties associated with the synthesis of the
aza-amino acid monomers and the restricted side chain diversity produced by reductive
amination.
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Scheme 2.1. The Fmoc/Ddz-strategies for azapeptide synthesis.9,10

A variety of methods have also been developed for preparing azapeptides by
activating the N-terminal amino group of a resin bound peptide into an isocyanate and
coupling with a suitable aza-amino acid monomer (Scheme 2.2). For example, aza-tri,
dipeptide and amino acid fragments have been prepared in solution and coupled onto the
activated N-terminus of peptide bound resin.8,11 In these approaches, multiple steps were
required to make the aza amino acid building blocks and the synthesis method was
contaminated with significant amounts of hydantoin. Reversible amide bond protecting
groups have since then been introduced to surmount the issues of hydantoin formation, albeit
with additional steps for the introduction and removal of the protecting group.12 Thus, azaamino acid or N-terminus peptide activation have been successfully employed for making
bio-active azapeptides. However, these methods are limited in their ability for producing a
combinatorial library of structurally diverse azapeptides for studying SARs with biological
targets.
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Scheme 2.2. N-terminal isocyanate activation and carbazate coupling strategy for azapeptide
synthesis.8,11
The previously described methods necessitated the preparation of the aza-amino acid
monomers in solution prior to their incorporation within azapeptide sequences by
conventional solid phase peptide synthesis (SPPS).7-12 A more direct and versatile approach
would be to build the aza-amino acid residue during the course of the azapeptide synthesis
method. Inspired by the un-natural peptide synthesis (UPS) approach developed by
O’Donnell13 and applied by others14, the submonomer azapeptide synthesis strategy6
circumvents the need for monomer preparation and does not require stereo-chemical control
for building the aza-residue on solid phase. Instead, the construction of the aza-amino acid
residue during SPPS requires the efficient introduction of a suitably protected aza-glycine
residue, its chemo-selective alkylation, deprotection and chain extension reactions. In the
submonomer approach (Scheme 2.3), aza-glycine has been incorporated at the N-terminus of
the peptide bound support by treating benzaldehyde hydrazone with p-nitrophenyl
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chloroformate and coupling the activated carbazate to form the N-terminal semicarbazone.
Regioselective semicarbazone alkylations introduced varying side chain groups at the azaglycine position. Semicarbazone deprotection and conventional SPPS15 were continued until
the desired azapeptides were produced. Thus, the submonomer azapeptide synthesis method
followed a three-step procedure inserted within the SPPS cycle (Scheme 2.3). The method
consisted of (1) activation and acylation of peptide bound resin with an activated benzylidene
carbazate, 2.12, formed in-situ upon the reaction of benzaldehyde hydrazone and pnitrophenyl chloroformate, (2) alkylation of the N-terminal semicarbazone, 2.13 and (3) its
deprotection yielded semicarbazide, 2.15, ready for (4) conventional Fmoc-based SPPS.6
Following step 3, the submonomer method may be repeated producing azapeptides with
several aza-residues within the sequence or the fully functionalized azatides.16 Completion of
the solid phase synthesis produced the protected azapeptides bound to their solid supports.
Azapeptide deprotection and cleavage from solid phase were finally accomplished for
analysis and purification which led to structure-function studies. In a nutshell, the
submonomer method was created to simplify azapeptide synthesis while providing greater
opportunity for the combinatorial library preparation of side chain diverse azapeptides for
SAR studies.
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Scheme 2.3. The submonomer solid phase azapeptide synthesis method.6
The submonomer approach has led to the solid phase synthesis of 10 aza-analogs of
GHRP-6 built from support bound aza-glycine alkylations with primary and secondary alkyl
halides (Figure 2.1).6 Among this series, the conformational and biological properties of
[aza-Phe4]-GHRP-6 evaluated by CD spectroscopy and receptor binding studies respectively
demonstrated a stable -turn favored selective CD36 receptor binding. Considering the antiangiogenic properties of GHRP-6 ligands that favor selective CD36 scavenger receptor
binding, [aza-Phe4]-GHRP-6 may become a promising lead for the development of treatments
for angiogenic disorders, such as age-related macular degeneration.
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Figure 2.1. Submonomer synthesis produced ten GHRP-6 azapeptides, from which the [azaPhe4]-GHRP-6 analog exhbited a 1000-fold increase in CD36 scavenger receptor binding
relative to the growth hormone secretagogue receptor (GHS-R1a). Figure adapted from
reference 6.

Expanding on the alkylation step, Michael additions of electron deficient olefins and
conjugate addition-elimination reactions of activated allylic acetates have produced aza-Glu
surrogates to explore the influence of turn conformation and carboxylate interactions on
azapeptide activity (Figure 2.2).17 Fifteen aza-Glu derivatives of GHRP-6 were prepared by
the submonomer approach, effectively expanding the repertoire of side chain diverse
azapeptides for SAR studies with receptor targets.

Moreover, aza-pyroglutamate and

pyrrazoline GHRP-6 analogs were prepared upon intramolecular cyclization of aza-Michael
acceptors with the N-terminal amine of the peptide sequence. Structural studies of the azaGlu peptides by NMR and CD spectroscopy demonstrated folded azapeptide conformations
which translated into varying degrees of CD36 receptor binding affinities, none of which
outperformed the [aza-Phe4]-GHRP-6 analog.
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Figure 2.2. Aza-Glu GHRP-6 azapeptide binding interactions to the CD36 scavenger
receptor. Figure adapted from reference 17.

Submonomer azapeptide synthesis has also produced 13 aza-arylglycine GHRP-6 analogs by
copper-catalyzed N-arylation of semicarbazone peptide bound support.18 The use of aryl and
heteroaryl iodides furnished azapeptides with side chains bearing resemblance to the aza-Phe,
aza-Tyr, aza-Trp and aza-His residues (Scheme 2.4). Substituion of the Trp4 position with
aza-arylglycine residues induced a β-turn conformation which may favor CD36 binding
affinity and selectivity.
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Scheme 2.4. Copper-catalyzed N-arylation of semicarbazone peptide bound support. Figure
adapted from reference 18.

Seven new GHRP-6 azapeptides containing aza-1,2,3-triazole-3-alanine residues were
prepared on aza-propargylglycine residues by a copper-catalyzed 1,3-dipolar cycloaddition
reaction with aryl azides (Scheme 2.5).19 This libraries-from-libraries methodology featured
further diversification of the aza-residues and led to the generation of new azapeptides that
may be useful for structure-activity studies.

Scheme 2.5. Copper-catalyzed 1,3-dipolar cycloaddition reaction with azapropargyl glycine
residues and aryl azides. Figure adapted from reference 19.
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The azapropargyl glycine residue was also used for the production of constrained azalysine peptides (Figure 2.3). Their synthesis was accomplished by a copper catalyzed
coupling of Mannich reagents to aza-propargylglycine residues. Eighteen aza-Lys GHRP-6
analogs were produced by the so-called A(3)-coupling reaction.20

Figure 2.3. Structure comparison of lysine and a constrained aza-lysine mimic. Figure
adapted from reference 20.

The submonomer method has also been used to modify the azapeptide backbone. For
example, 4-substituted N-amino-imidazolin-2-one peptides were synthesized by a basepromoted cyclization of aza-propargylglycine residues.21 Further diversification of the Namino-imidazolin-2-one scaffold was accomplished by a tandem Sonogashira cross-coupling
and cyclization reaction with aryl and heteroaryl iodides to modify the 4-position of the
imidazolin-2-one. These peptide mimics revealed a type II’ β-turn conformation according to
X-ray crystallography and circular dichroism spectroscopy supported the presence of a turn
conformation. This privelged structure led to tight binding affinity for the CD36 receptor, and
inhibitory activity on MAP kinase JNK phosphorylation, that are all indicative of modulating
scavenger receptor activity. In a related application,

N-amino-imidazolidin-2-one

peptidomimetics have also been achieved by alkylation and cyclization of the urea nitrogen
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of a semicarbazone using ethylene bromide. The syntheses and isolation of 25 N-aminoimidazolidin-2-one peptidomimetics have been developed by an extension of the
submonomer azapeptide synthesis method.22

Figure 2.4. Structure of N-amino-imidazolin-2-one. Figure adapted from reference 21-22.

Thus, submonomer solid phase azapeptide synthesis has effectively expanded the repertoire
of side chain diverse azapeptides useful in studying the effects of the -nitrogen
configuration, backbone conformation and side chain structure on biological activity.

2.3 CHAPTER OBJECTIVES
In this chapter, the synthesis and characterization of a new class of azapeptide inhibitors
of the insulin receptor tyrosine kinase (IRTK) will be described.23 The azapeptide ligands are
derived from the activation loop of the IRTK which encompass the Ac-DIYET-NH2, 2.28,
sequence. Submonomer azapeptide synthesis will be employed to develop a small library of
azapeptide analogs of the native sequence to identify the influence and location of turn
structure on IRTK inhibitory activity. Specifically, the IYE pharmacophoric region of 2.28
will be systematically replaced with aza-amino acid residues to facilitate our aza-amino acid

Page 38 of 172

scanning strategy (Figure 2.5). Following azapeptide synthesis, LCMS analyses and
purification, the isolated azapeptides will be employed for SAR studies (Chapters 3 and 4).

Figure 2.5. Aza-amino acid scanning of Ac-DIYET-NH2, 2.28, for IRTK inhibitory
activity.23
2.4 RESULTS AND DISCUSSION
The native sequence Ac-DIYET-NH2 2.28 and an analog Ac-DIFET-NH2 2.43 were
synthesized by SPPS using Rink amide AM resin in 75% isolated yields. The submonomer
approach was adopted and optimized for the preparation of azapeptide analogs of the AcDIYET-NH2, 2.28, sequence. Reaction conditions were initially developed for AcDIazaYET-NH2, 2.36. This methodology consisted of an activation and coupling step, which
facilitated the introduction of an activated carbazate intermediate, 2.30, onto the peptide
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bound support, 2.31, to generate the N-terminal semicarbazone, 2.32. Regioselective
alkylation was next accomplished by a tandem halogen exchange and alkylation reaction.
Halogen exchange of 4-benzyloxybenzyl chloride and sodium iodide24 resulted in the
formation of 4-benzyloxybenzyl iodide in-situ. The more reactive benzyl iodide was used as
alkylating reagent with the non-ionic Schwesinger phosphazene-base, tert-butyliminotri(pyrrolidino)phosphorane, BTPP25 to generate the alkylated semicarbazone, 2.33. No
alkylation was observed by the reaction of 4-benzyloxybenzyl chloride, BTPP and the
semicarbazone bound support, highlighting the importance of the halogen exchange step to
yield the more reactive 4-benzyloxybenzyl iodide electrophile. Following alkylation,
transamination of the N-terminal semicarbazone, 2.33, to generate semicarbazide, 2.34, was
completed in a pre-set incubator (60 oC, 100 rpm, 12 h) by treating the resin in a solution of
hydroxylamine hydrochloride buffered in pyridine (1.5 M). These mild conditions were
found to be chemo-selective for the removal of the semicarbazone group while leaving the
side chain protecting groups in-tact and minimizing the premature cleavage of the azapeptide
from the solid support. Following semicarbazone deprotection, conventional solid phase
peptide synthesis15, was used to complete the partially protected azapeptide, 2.35. Attempts
for the removal of the aza-Tyr benzyl protecting group from the azapeptide bound support
were unsuccessful on solid phase, resulting in minor deprotection yields and concomitant side
product formation. Therefore, the azapeptide was cleaved from the Rink amide-linked
polysytrene solid support26 and deprotection of the acid-labile side chain protecting groups
were accomplished in TFA with H2O and TES scavenging the reactive tetrabutyl carbonium
ion species.27 The removal of the aza-Tyr benzyl protecting group was next accomplished in
solution by a Pd/C catalyzed hydrogenolysis reaction8 which finally afforded the desired AcDIazaYET-NH2, 2.36, (Scheme 2.6). Following purification and characterization by RP-
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LCMS, 2.36, was isolated in yields of 50% and purities >95% as ascertained by RP-LCMS
(Figure 2.6).

Scheme 2.6. Submonomer solid phase synthesis of Ac-DIazaYET-NH2 (2.36).
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Figure 2.6. LCMS spectra of Ac-DIazaYET-NH2, 2.36.
Azapeptide analogs targeting the IYE pharmacophoric region of the parent
pentapeptide Ac-DIYET-NH2, 2.28, were next prepared by the established submonomer
synthesis method (Scheme 2.6) and characterized by RP-LCMS (Table 2.1). At the 2
position, [aza-Ile2] and [aza-Ala2] residues were introduced respectively by alkylation with 2iodobutane and methyl iodide in the presence of BTPP. The [aza-Gly2]-residue was recovered
without alkylation to generate azapeptides (2.37-2.39) in isolated yields of 51-55% and
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purities > 95%. Of note, the aza-Ile residue was synthesized in racemic form due to the
achiral 2-iodobutane used as alkylating reagent. However, a single azapeptide diastereomer
for 2.38 was isolated by RP-LCMS for structure-activity relationship studies. Moving to the 3
position, the [aza-Phe3] residue was constructed with KOtBu as base and benzyl bromide as
alkylating reagent to produce the Ac-DIazaFET-NH2, 2.40, analog, in good yields (43%) and
isolated purities (96%) according to RP-LCMS analyses. In the case of [aza-Tyr3], and [azaDOPA3], halogen exchange reactions24 converting the alkylating reagents 4-benzyloxybenzyl
chloride and 3,4-dibenzyloxybenzyl chloride, respectively, to their corresponding alkyl
iodides in the presence of BTPP improved yields (36-50%) and purities >95% for the desired
azapeptides (2.36, 2.41). At the 4 position, [aza-Glu4] was installed using Michael addition
chemistry17 with KOtBu and tert-butyl acrylate to generate Ac-DIYazaET-NH2, 2.42, in
isolated yields of 42% and 96% purity.
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Table 2.1. Characterization data of azapeptides synthesized in this study.

a

Crude purity by RP-LCMS at 214 nm using 2-90% MeOH in H2O with 0.1% FA over 15

min. bIsolated purity by RP-LCMS at 214 nm using 2-90% MeOH in H2O with 0.1% FA over
15 min. cCalculated from resin loading. dObserved mass (expected mass) as [M+H]+ or [MH]- by ESI-MS in positive or negative mode. Retention times (min) by RP-LCMS at 214 nm
using 2-90% eMeOH or fMeCN in H2O with 0.1% FA over 15 min.
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2.5 CONCLUSIONS
In conclusion, a new class of azapeptide analogs of the Ac-DIYET-NH2, 2.28,
sequence were constructed by submonomer synthesis. Submonomer solid phase synthesis
furnished a small library (7) of azapeptides featuring the introduction of new aza-Ile and azaDOPA residues. Halogen exchange reactions were found to be particularly well suited for the
introduction of aza-Tyr and aza-DOPA residues at the Tyr3 position. These reactions were
used to convert the poorly reactive benzyl chlorides to the more reactive iodides which
furnished azapeptide, 2.36 and 2.41 in 50 and 36% yields, respectively. The aza-isoleucine
analog was synthesized using racemic 2-iodobutane as alkylating agent in the presence of
BTPP. Although this resulted in diastereomeric Ac-DazaIYET-NH2, 2.38, RP-LCMS
purification and analysis provided a single diastereomer, suitable for SAR studies.
Azapeptides were isolated in sufficient yields (36-55%) and good purities (>95%) following
submonomer synthesis and RP-LCMS purification. Thus, the submonomer approach for
azapeptide synthesis proved to be an efficient methodology for the combinatorial preparation
of azapeptides useful for structure-function studies. With purified constructs in hand,
opportunity now exists for exploring influence of azapeptide configuration, conformation and
side chain interactions on IRTK binding and inhibitory activity (Chapters 3 and 4).
2.6 EXPERIMENTAL SECTION
Materials. Fmoc-Asp(OtBu), Fmoc-Ile, Fmoc-Tyr(t-Bu), Fmoc-Glu(t-Bu) and FmocThr (t-Bu) and Fmoc-Phe were purchased from Novabiochem™ (EMD Millipore) and used as
received. Polystyrene Rink Amide AM resin (0.79 mmol/g) was purchased from
Novabiochem™ (EMD Millipore), and the manufacturer’s reported loading of the resin was
used in the calculation of the yields of the final products. Reagents used for the submonomer
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solid phase synthesis of azapeptides include, tert-butyl acrylate (TCI), 3,4-dibenzyloxybenzyl
chloride (Acros), hydroxylamine hydrochloride (Alfa Aesar), potassium t-butoxide (Aldrich),
N,N-diisopropylcarbodiimide, DIC (TCI), N-methylmorpholine, NMM (Acros), piperidine,
N,N-diisopropylethylamine, DIEA (Aldrich), triethylsilane, TES (Alfa Aesar), benzyl
bromide BnBr (TCI), 4-nitrophenyl chloroformate (Alfa Aesar), palladium 10% weight on
activated carbon, Pd/C (Aldrich), acetic anhydride, Ac2O (Mallinckrodt) hydrazine hydrate
(Alfa Aesar), trifluoroacetic acid TFA (Alfa Aesar), pyridine (Alfa Aesar), 2-iodobutane
(TCI), 4-benzyloxybenzyl chloride (Aldrich), iodomethane (Alfa Aesar), tert-Butyliminotri(pyrrolidino)phosphorane, BTPP (Aldrich), N,N-dimethylformamide DMF (Macron),
formic acid FA (Aldrich), dichloromethane DCM (Macron), methanol MeOH (Macron),
acetone Ace (Macron), acetonitrile MeCN (Macron), tetrahydrofuran THF (BDH) and

O-

(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HCTU
(Creosalus).
Fmoc-based Solid Phase Peptide Synthesis.
Peptide syntheses were performed under standard Fmoc-SPPS conditions15 on a PSI
200C Peptide Synthesizer (Peptide Scientific, New York NY) using Polystyrene Rink Amide
AM resin (0.79 mmol/g). Couplings of amino acids (3 equiv.) were performed in DMF using
HCTU (3 equiv.) as coupling reagent and NMM as base (6 equiv.). About 5 equiv. of amino
acids and HCTU and 10 equiv. of NMM were used for the coupling of the first amino acid
[Fmoc Thr(t-Bu)] to the resin. Fmoc deprotections were performed by treating the peptide
bound resin with 20% piperidine in DMF for 20 min. The resin was washed after each
coupling and deprotection steps with DMF (3 x 10 mL). N-terminal acetylation was
performed by addition of acetic anhydride (0.1 mmol, 50 equiv. 472 µL) and pyridine (400
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µL) in DMF (1.5 mL). The reaction was continued for about 20 minutes on an overhead
shaker. The peptide bound resin was vacuum filtered and washed with DMF (3 x 10 mL),
MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL). The purity of di-, [Glu-ThrCONH2] tri-, [Tyr-Glu-Thr-CONH2] & [Phe-Glu-Thr-CONH2] and tetra- [Ile-Tyr-Glu-ThrCONH2] & [Ile-Phe-Glu-Thr-CONH2] peptide fragments were ascertained by molecular
weight confirmation using ESI-LCMS following cleavage and deprotection of small aliquots
of resin. After each step during the synthesis of control sequences as well as azapeptides,
reaction monitoring and verification of the products, were performed by LCMS.
Cleavage test of resin-bound peptide. A small portion of the peptide bound resin (35 mg) was treated with a freshly made solution of TFA/H2O/TES (95:2.5:2.5, v/v/ v, 0.5 mL)
for about 30 min at room temperature. The cleavage mixture was filtered and then
concentrated under air or nitrogen and crude peptide was precipitated with cold ether (1.5
mL). Crude peptide samples were agitated on a vortex shaker, and spun in a centrifuge
followed by decantation of the supernatant which left a pellet that was dissolved in 50%
MeCN/H2O (about 1 mg/mL) and injected in LCMS for analyses.
Submonomer azapeptide synthesis.
Representative protocol for aza-Gly peptide synthesis, preparation of semicarbazoneazaGly-Glu(t-Bu)-Thr(t-Bu) Rink amide AM resin (2.32).
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To a stirred solution of EtOH (1.5 mL) in a vial equipped with a magnetic stirrer at 0 oC, was
added hydrazine hydrate (56 μL, 1.8 mmol). To this reaction mixture, dropwise addition of
benzaldehyde (61 μL, 0.6 mmol) was added. The reaction progress was tracked by TLC, [(2:1
Hexane:EtOAc), Rf (benzaldehyde): about 0.7 and Rf (benzaldehyde hydrazone): about 0.6]
which indicated complete reaction in about 15 min. The reaction mixture was quenched in
H2O (5 mL) and the desired benzaldehyde hydrazone was extracted with DCM (3 x 5 mL).
The organic phase was dried with anhydrous MgSO4 or Na2SO4, concentrated to yield the
crude product (70 mg, 98%) that was employed without further purification.
Benzaldehyde hydrazone (70 mg, 0.6 mmol, 3 equiv.) was dissolved in DCM (1 mL) and
added dropwise over 15 min to a solution of p-nitrophenyl chloroformate (123 mg, 0.61
mmol, 3.2 equiv.) in DCM (1 mL) at 0 oC. The reaction mixture was warmed to room
temperature (22 oC) and stirred for an additional 1.5 h under nitrogen. Complete conversion
of the starting material to the activated carbazate intermediate, 2.30, was confirmed by TLC
[(2:1 Hexane:EtOAc), Rf: 0.75]. DIEA (210 μL, 1.2 mmol, 6 equiv.) was added to neutralize
the reaction mixture (20 min at 0oC) and the suspension was added to the resin for the
coupling reaction. This reaction was mixed on an automated shaker for 16 h at room
temperature. The next day, the resin was filtered and washed under vacuum with DMF (3 x
10 mL), MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL). The reaction
conversion was monitored by analyzing a small sample of resin (~3 mg) by LCMS following
peptide cleavage and deprotection [1 mL, TFA/TES/H2O (95:2.5:2.5, v/v/v)] from the solid
support.
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Benzaldehyde semicarbazone-azaGly-Glu-Thr-CONH2 (2.32). ESI-LCMS [2-90% MeOH
in H2O (0.1% FA), 15 min] RT = 6.5 min; Calculated for C13H23N5O6 [M+H]+ 394.1 found
m/z 394.1.
Representative alkylation of aza-Gly, preparation of semicarbazone-azaTyr(OBn)Glu(t-Bu)-Thr(t-Bu) Rink amide AM resin (2.33).

For benzyl chloride derivatives, Finkelstein reactions24 were performed by dissolving 4benzyloxybenzyl chloride (140 mg, 0.1 mmol, 6 equiv.) and NaI (180 mg, 1.2 mmol, 12
equiv.) in acetone (1 mL). The reaction was refluxed overnight (16 h) for the production of 4benzyloxybenzyl iodide. The reaction mixture was quenched with water (3 mL) and extracted
with ether (2 x 10 mL). The ether layer was isolated and dried over anhydrous MgSO4 and
the solution was evaporated to dryness under vacuum.
The semicarbazone peptide bound resin 2.32 (0.1 g, 67 μmol) was swollen in THF (1 mL),
and BTPP (92 µL, 0.1 mmol, 3 equiv.) was added to activate the semicarbazone for the
alkylation reaction. The mixture was agitated on an automated shaker for about 20 min, and
then treated with 4-benzyloxybenzyl iodide (196 mg, 0.1 mmol, 3 equiv.) at room
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temperature for an additional 16 h. The resin was filtered, then washed with DMF (2 x 10
mL), MeOH (2 x 10 mL), THF (2 x 10 mL), and DCM (2 x 10 mL) and dried under vacuum.
The extent of reaction was monitored by sampling an aliquot (~3 mg) of resin which was
subjected to 1 mL of TFA/TES/H2O (95:2.5:2.5, v/v/v) for cleavage and deprotection of the
crude peptide.

Benzaldehyde semicarbazone-azaTyr(OBn)-Glu-Thr-CONH2 (2.33). ESI-LCMS [2-90%
MeOH in H2O (0.1% FA), 15 min] RT = 12.5 min; Calculated for C31H35N5O7 [M+H]+,590.2
found m/e 590.2.
Representative protocol for semicarbazone removal, preparation of azaTyr(OBn)-Glu(tBu)-Thr(t-Bu) Rink amide AM resin (2.34).

The resin-bound semicarbazone 2.33 (0.1 g, 67 μmol) was treated with a solution of 1.5 M
NH2OH.HCl in pyridine (2.5 mL) and the semicarbazone transamination reaction was
completed in a pre-set incubator (60 oC, 100 rpm, 12 h) to liberate the resin bound
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semicarbazide 2.34. The resin was filtered and washed under vacuum with DMF (3 x 10 mL),
MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL). The extent of the reaction was
monitored by ESI-LCMS, by cleaving and deprotecting an aliquot (~3 mg) of resin with
TFA/TES/H2O (1 mL, 95:2.5:2.5, v/v/v).

azaTyr(OBn)-Glu-Thr-CONH2 (2.34). ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15
min] RT = 8.5 min; Calculated for C24H31N5O7 [M+H]+,502.2 found m/z 502.2.
Preparation of Asp(t-Bu)-Ile-azaTyr(OBn)-Glu(t-Bu)-Thr(t-Bu) Rink amide AM resin
(2.35).

Fmoc-Ile (353 mg, 0.67 mmol, 10 equiv.) and diisopropylcarbodiimide (77 µL, 0.34 mmol, 5
eq) in DCM (1 mL) were reacted for 20 min on ice. The suspension was then concentrated invacuo, dissolved in DMF (1 mL), and added to semicarbazide peptide resin 2.34 (0.1 g, 67
μmol) for the coupling reaction. This reaction was continued for an additional 16 h at room
temperature (22 oC) and the resin was filtered and washed under vacuum with DMF (3 x 10
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mL), MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL). Fmoc deprotection was
performed by addition of 20% piperidine in DMF (2 mL) and the reaction was continued on
an overhead shaker for 20 minutes at 22o C. Upon completion of the Fmoc deprotection
reaction, the azapeptide bound resin was vacuum filtered, washed with DMF (3 x 10 mL),
MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL).
Fmoc-Asp(t-Bu) (123 mg, 0.3 mmol, 3 equiv.), HCTU (124 mg, 0.3 mmol, 5 equiv.) and
NMM (66 µL, 0.6 mmol, 6 equiv.) were dissolved in DMF (1 mL) and added to the resin.
The reaction was agitated on an overhead shaker for 30 min. The resin was then filtered and
washed under vacuum with DMF (3 x 10 mL), MeOH (3 x 10 mL), THF (3 x 10 mL), and
DCM (3 x 10 mL). Fmoc deprotection was then performed as previously described. The
sample crude purity was analyzed by ESI-LCMS by subjecting an aliquot (~3 mg) of resin to
the cleavage and deprotection conditions [1 mL, TFA/TES/H2O (95:2.5:2.5, v/v/v)].

Asp-Ile-azaTyr(OBn)-Glu-Thr-CONH2 (2.35). ESI-LCMS [2-90% MeOH in H2O (0.1%
FA), 15 min] RT = 8.5 min; Calculated for C24H31N5O7 [M+H]+, 615.3 found m/z 615.3.
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Preparation of Ac-Asp-Ile-azaTyr-Glu-Thr-CONH2 (2.36).

N-terminal acetylation was performed by addition of acetic anhydride (0.1 mmol, 50 equiv.
472 µL) and pyridine (400 µL) in DMF (1.5 mL). The reaction was continued for about 20
minutes on an overhead shaker. The peptide bound resin was vacuum filtered and washed
with DMF (3 x 10 mL), MeOH (3 x 10 mL), THF (3 x 10 mL), and DCM (3 x 10 mL). The
extent of reaction was monitored by subjecting an aliquot (~3 mg) of resin to cleavage
conditions [1 mL, TFA/TES/H2O (95:2.5:2.5, v/v/v)] and analyzing the crude by LCMS. The
azapeptide (0.2 mmol) was then dissolved in ethanol:water (1 mL, 50:50 v/v) and 10% Pd/C
catalyst (20 mg) was added to the solution. A hydrogen filled balloon was placed over the
reaction vessel and the reaction was continued overnight at room temperature (22 oC). The
solution was filtered and lyophilized to a dry powder followed by LCMS analysis as
previously described.
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Ac-Asp-Ile-Aza-Tyr-Glu-Thr-CONH2 (2.36). ESI-LCMS [2-90% MeOH in H2O (0.1%
FA), 15 min] RT = 10.1 min; Calculated for C36H49N7O12 [M-H]-, 681.3 found m/z 681.2.

Complete deprotection and cleavage of azapeptides (2.36-2.42) from the resin.
The Rink resin-bound azapeptides were deprotected and cleaved from the support using
freshly made solutions of TFA/H2O/TES (95:2.5:2.5, v/v/v, 20 mL/g of peptide resin) at
room temperature for 2.5 h. The resin was filtered and rinsed with 1 mL of TFA. The filtrate
and rinses were concentrated under a flow of N2(g) until a crude oil persisted. Cold ether (1015 mL) was then added to crude oil to precipitate the peptide. Following centrifugation (1200
rpm for 10 min.), the supernatant was removed and the crude peptide was taken up in
aqueous MeCN or MeOH (10% v/v in water) and freeze-dried to a white solid prior to
analysis.
Analyses and purification of azapeptides (2.36-2.42).
Analyses and characterization of crude azapeptides were accomplished on either an
AgilentTM Technologies 1100 Series LCMS instrument with ESI ion-source, single
quadropole mass detection and positive or negative mode ionization or a Waters Alliance
HPLC system equipped with a photodiode array detector (PDA) for azapeptide analyses at
214 nm. Azapeptide samples were dissolved in 50% H2O in acetonitrile or methanol (1
mg/mL). The LCMS analyses were performed on a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm), using binary solvent system consisting of 0.1% formic acid
in H2O (Mobile phase A), and 0.1% formic acid in methanol (Mobile phase B) at a flow rate
of 1.0 mL/min and UV detection at 214 nm. Linear gradients of the mobile phase (0.1%
formic acid in methanol, 2-90% over 15 min) were used for analyses of the crude
azapeptides.
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Purification of azapeptides was conducted on a WatersTM PrepLC instrument
equipped with a reverse-phase YMC pack ODS A column (250 × 20 mm, 5 μm), using
binary solvent system consisting of 0.1% formic acid in H2O, and 0.1% formic acid in
methanol at a flow rate of 15 mL/min and UV detection at 214 nm. Linear gradients of the
mobile phase (0.1% formic acid in methanol, 2-90% in 15 min) were used for purifications of
azapeptides. Fractions containing pure azapeptides were combined, freeze-dried and
lyophilized to a white powder. Purified azapeptide samples were analyzed for purity by
LCMS with a Symmetry Sheild C18 reverse-phase column (150 × 4.60 mm, 3.5 μm), with a
flow rate of 1.0 mL/min using a 2-90% gradient from water (0.1% FA) to CH3CN (0.1% FA)
or to MeOH (0.1% FA) as previously described.
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CHAPTER
3:
AZAPEPTIDE
STRUCTURAL
STUDIES
MOLECULAR MODELING, CD AND NMR SPECTROSCOPY

3.1

BY

ABSTRACT
The structural characterization of the azapeptide analogs (Table 2.1, sequence no.

2.36-2.42) of the Ac-DIYET-NH2, sequence were performed by molecular modeling and
docking simulations, circular dichroism (CD) and NMR spectroscopy. Computational
analyses were initially performed to determine the structural differences between the
azapeptide analog, Ac-DIazaYET-NH2, sequence 2.36 and its parent sequence, 2.28.
Interestingly, the azapeptide sequence, 2.36, was found to maintain a turn-type geometry
which translated into tight binding affinity (< 5Å) within the active site of the insulin receptor
tyrosine kinase (IRTK) domain. The structural properties of the azapeptides synthesized in
this study (Chapter 2, Table 2.1) were further analyzed by CD spectroscopy to determine
trends in peptide folds in aqueous media (H2O and phosphate buffered saline, PBS) and
organic solvent (dimethyl sulfoxide, DMSO). The peptides were found to exhibit secondary
structural features which contained both random and turn conformations that were contingent
on solvent, sequence and position of the aza-amino acid substitutions. Specifically, the CD
spectrum of the parent peptide Ac-DIYET-NH2 (2.28), was compared to that of the
azapeptide, Ac-DIazaYET-NH2 (2.36). The insertion of the [aza-Tyr3] residue within the i+2
position of the native sequence was found to stabilize a -turn conformation. NMR
spectroscopy confirmed the azapeptide β-turn structure by providing evidence of the
intramolecular hydrogen bonding interaction in between the CO at the i and the NH at the
i+3 position. Moreover, 2D NOESY correlation studies supported the azapeptide fold,
highlighting the influence of the [aza-Tyr3] residue in locking the turn-type geometry. In light
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of the stable azapeptide folded structures which may translate into IRTK binding and
inhibitory activity, a structural study is presented within this chapter and concluded with the
biological activity of the azapeptides in Chapter 4 of this thesis.

3.2
3.2.1

INTRODUCTION
AZAPEPTIDE STRUCTURE AND CONFORMATION
Introduction of an aza-amino acid within a peptide sequence provides a unique

conformational change within the peptide backbone, resulting in a stable turn-type secondary
structure.1 Several model systems were designed and examined to understand the
conformational properties of azapeptides. For example, the conformations of a 1,2diacylhydrazine, which mimics the semicarbazide moiety found within azapeptides, were
investigated by computational analyses. These studies indicated that the 1,2-diacylhydrazine
adopted a nonplanar global minimum structure in which the nitrogen lone pairs were
essentially perpendicular to one another.2-6 Azapeptide conformation is dictated by the
dihedral angles φ (NH-Nα) and ψ (Nα – CO). A variety of computational, spectroscopic and
crystallographic methods have been used to study the conformational properties of
azapetides. These studies have shown that azapeptides prefer a narrow range of dihedral
angle values (φ = 90◦ ± 30o or -90◦ ± 30º and ψ = 0◦ ± 30◦ or 180◦ ± 30◦) which correspond
closely to different types of β-turn secondary structures (Figure 1.2, Table 1.1).7 Introduction
of a semicarbazide residue within a peptide chain causes significant restriction of the peptide
backbone favoring nonlinear conformations which mimics several known types of -turn
structures found in naturally occurring peptides and proteins.8 Significantly, the stabilized turn conformations found within azapeptides have translated into improved peptide biological
activity, underscoring their potential in medicinal chemistry applications.9-11
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3.2.2 COMPUTATIONAL ANALYSES
Computational docking experiments of the pentapeptide, Ac-DIYET-NH2, 2.28, with
the IRTK binding domain were performed with DOCK 6 and its accessories programs.12
These binding simulations illustrated a folded peptide structure reminiscent of a turn
conformation which may contribute to binding affinity (Figure 3.1).12 The docking studies
showed that binding site occupied by Ac-DIYET-NH2, 2.28, consisted of an ATP binding site
and the catalytic loop. Two key residues, Asp 1132 and Arg 1136, found within the catalytic
loop of the insulin receptor played a crucial role in the IRTK phosphorylation reactions and
may be considered optimal locations for peptide inhibitory activity. According to the IRTK
binding studies, the pentapeptide ligand, Ac-DIYET-NH2, 2.28, was found near the catalytic
site, with the threonine residue interacting with Asp 1132 and Arg 1136 of the IRTK,
presumably through hydrophobic and H-bonding interactions. The binding interactions of
Ac-DIYET-NH2, 2.28, with these 2 key IRTK binding site residues may prevent the entry of
ATP substrate to the catalytic site of the receptor. Consequently, IRTK autophosphorylation
and activation of its signaling pathways are inhibited. Thus, peptide analogs that may
stabilize the bio-active conformation responsible for IRTK binding may lead to the
generation of more potent inhibitors of this important receptor.
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Figure 3.1. Binding model of the pentapeptide ligand, Ac-DIYET-NH2, 2.28 within the
active site of the IRTK. Figure adapted from reference Kato, M. et al. J. Pept. Sci. 2009, 15,
327.12
3.2.3 CD SPECTROSCOPY
Circular Dichroism (CD) spectroscopy is a powerful method in structural biology,
useful for the conformational analysis of peptides and proteins. CD spectroscopy is a measure
of the difference in light absorption of right versus left-handed polarized light.13 When
asymmetric molecules such as peptides absorb circularly polarized light, a CD signal that is
characteristic of the peptide conformation (ellipticity) as a function of wavelength in the UV
(190 - 350 nm) region is generated. Therefore, the CD spectrum provides a unique trace that
is contingent on the nature of the chromophores and the asymmetric structure of the peptide.
More specifically, CD spectroscopy is an excellent tool for the rapid evaluation of
peptide secondary structures. It may also be useful in determining the various folding patterns
of peptides and their mimics, the stabilities of their secondary structures and may also
provide valuable information on their binding properties with ligands and receptor targets.14
Thus, CD spectroscopy is a useful characterization technique for studying peptide secondary
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structures in order to gain greater insight into their structure-activity relationships. Although
other methods may also be used to evaluate peptide structures, including computational
analyses15, mass spectrometry16, nuclear magnetic resonance (NMR) spectroscopy17 and Xray crystallography18, the CD study retains the ability to produce quick spectra for a wide
range of peptide samples in solution relative to these other laborious techniques.13,14 This is
because CD spectroscopy provides a non-destructive method for sample analyses while
providing opportunity for exploring peptide structure, bio-physical and biological properties.
The chirality of the peptides along with their ability to absorb electromagnetic
radiation in the far (190 – 260 nm) and near (260 – 350 nm) UV region make them well
suited for conformational analysis by CD spectroscopy. The CD spectrum in this region is
dominated by the n→π* (C=O) and π→π* (N-CO) transitions of the amide groups and are
reflective of the peptide backbone geometry. The electronic transitions of the peptide
functional groups in the far UV-region and the asymmetric peptide geometry produces a CD
spectrum that is contingent on the peptide secondary structure. Peptide coils, helices, sheets
and turn conformations have all been characterized by CD spectroscopy (Figure 3.2, i).13,14 A
random coil has a broad positive n→π* electronic absorption transition at 210 nm and a
negative π→π* transition at 190 nm. The -sheet peptide secondary structure has a negative
π→π* transition from 230 - 210 nm and a positive n→π* transition at 196 nm. Peptide turns
have positive n→π* transitions in between 220 and 200 nm and a negative band at 190 nm.
The CD spectra for α-helices have negative bands at 222 nm and 208 nm and a positive band
near 190 nm. In addition to these characteristic electronic absorptions, CD spectroscopy
provides information on the asymmetric peptide backbone geometry, that is dictated by the φ
and ψ torsion angles (Figure 3.2, ii).13,14,19
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Figure 3.2. Peptide secondary structure analyses i. Far UV (180 – 260 nm) CD spectra
associated with peptide secondary structures: solid curve, α-helix; long dashes, anti-parallel
β-sheet; dots, type I β-turn; dots and short dashes, random coil. ii. Peptide dihedral angles (φ,
ψ) associated with the -helix, -sheet and -turn peptide secondary structures.13,14,19

3.2.4 NMR SPECTROSCOPY

NMR spectroscopy has been used to determine the primary sequences and to study the
secondary structures of short model peptides in solution.20-24 This is primarily due to the
interaction of radiofrequency radiation in an oriented magnetic field with nuclei (1H,
15

13

C,

N) that are sensitive to NMR spectroscopy. Considering peptides contain an abundance of

NMR sensitive nuclei for analyses, various direct detection (1H and

13

C NMR) and

correlation experiments (1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HMQC, 1H15

N HSQC) have been used to sequence the amino acid residues found within peptides and

for mapping their secondary structures. Deuterated solvents are used in NMR spectroscopy to
calibrate the instrument to the radiofrequency for detection and to minimize the overlap of
solvent signals with sample. Moreover, deuterated solvents (i.e. DMSO-d6 or CDCl3 /
DMSO-d6 mixtures) that minimize exchange of deuterium with sample protons that are acidic
or protic in nature (e.g. –OH, -COOH, -NH2) have been used to characterize peptide
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secondary structures. In these deuterated solvent systems, peptide H-bonding interactions that
maintain their secondary structures may be detected. Moreover, protons that are solvent
exposed and not implicated in peptide folds will produce larger chemical shift changes that
are sensitive to solvent and temperature changes. For example, in the NMR study of a model
azapeptide, Boc-Ala-Phe-azaLeu-Ala-OMe, the amide proton of Ala4 was undisturbed by the
switch from chloroform to DMSO-d6, indicative of its involvement in an intramolecular
hydrogen bond.24 Additionally, 2D NOESY experiments may also be used to characterize the
nature of the peptide fold by determining which protons are within close NOE (< 5Å) contact
distances. In CDCl3, the model azapeptide indicated that the amide proton of the [azaLeu3]
residue exhibited strong and medium NOE, respectively with the α-proton of [Phe2] and the
amide proton of [Ala4], suggesting a type II β-turn with the aza-residue located in the i+2
position (Figure 1.5).24
3.3

CHAPTER OBJECTIVES
Azapeptide analogs of the Ac-DIYET-NH2 sequence, 2.28, presented in Chapter 2

will be further investigated in this chapter to determine their structural properties. The
structural studies will be initially performed by computational analyses. Molecular modeling
will be used to explore the influence of the aza-amino acid residue on azapeptide
conformation in silico. The Ac-DIazaYET-NH2 sequence, 2.36, and its parent peptide, AcDIYET-NH2, 2.28 will be used in a proof-of-concept study to explore the influence of the
[aza-Tyr3] residue on peptide backbone configuration and secondary structure. Following
conformational analyses of 2.28 a molecular docking simulation study will be conducted to
determine the likelihood azapeptide, 2.36, will bind to the active site of the IRTK. As suitable
controls, these binding experiments will be performed in comparison to the parent
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pentapeptide, Ac-DIYET-NH2, 2.28, and the natural ATP ligand of the IRTK. These
simulation experiments will pave the way for structure-activity relationship studies of the
azapeptides. CD and NMR spectroscopy will be used to confirm the azapeptide structures in
solution. These techniques are especially useful for the rapid and precise elucidation of
peptide conformational properties which will serve to validate the computational studies.
Moreover, these spectroscopic studies will be useful in supporting the putative -turn
secondary structures found within the azapeptide analogs of the Ac-DIYET-NH2, 2.28,
sequence. These azapeptides may prove to be useful ligands for the IRTK and related
tyrosine kinases for studying enzyme kinetics, mechanisms of action and in regulating their
biological activity for therapeutic applications (Chapter 4).
3.4

RESULTS AND DISCUSSION

3.4.1

MOLECULAR MODELING AND DOCKING STUDIES
The binding model of the parent pentapeptide Ac-DIYET-NH2, 2.28, with the IRTK

has shown that the peptide ligand is positioned near ASP 1132 and ARG 1136, two key
residues found within the catalytic loop of the receptor and involved in the
autophosphorylation reactions.12 Molecular docking studies were performed to gain a better
understanding of the binding model of the azapeptide analog, Ac-DIazaYET-NH2, 2.36, for
the kinase domain of the insulin receptor.
The crystal structure of the IRTK domain (Ser981- Lys1283) bound with ATP and a
peptide (KKKLPATGDYMNMSPVGD) was available from Protein Data Bank (PDB ID #
1IR3, and downloaded from the website (Figure 3.3).25
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Figure 3.3. Crystal structure of the IRTK downloaded from the Protein Data Bank (PDB ID
# 1IR3).25
The crystal structure of the IRTK was saved as a PDBQT file and transported within
AutoDock Tools to generate grid functions for the docking simulation studies. A molecular
docking study was performed with the azapeptide analog Ac-DIazaYET-NH2, 2.36, in
relation to the native peptide Ac-DIYET-NH2, 2.28, to visualize the binding interactions of
the modified peptide with the catalytic loop of the IRTK. An interface between the molecular
graphics system PyMOL and the molecular docking suite AutoDock Vina26 was used to
demonstrate the combination of docking and visualization models. AutoDock tools were used
to generate the PDBQT files of the receptor and the ligands. Vina is the program which
performed the docking and its output files were in PDBQT format. The output files were
visualized using PyMOL for evaluation of the binding models. The ligand was enclosed in a
box with a number of grid points in x, y, z directions, 20 x 22 x 16 and a grid spacing of 1.0
Ả. The center of the grid was set to -23.906, 30.439 and 12.466. Vina has generated 9
possible models of the azapeptide analog Ac-DIazaYET-NH2, 2.36, binding to the catalytic
loop of IRTK. The affinity of these candidates at 37 ºC and the probability of their docked
conformations were computed according to the Arrhenius equation (Table 3.1). The first
three candidates were found to be very similar in probability, differing by only about 2.5%.
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The visualization of the binding models by PyMOL displayed similar docking locations for
the azapeptide, 2.36. For the docking studies, the lowest energy docked conformation,
according to the AutoDock scoring function was selected as the binding model. The results
indicated that the proposed Ac-DIazaYET-NH2, 2.36, ligand also binds to the catalytic loop
of the IRTK, and in closer proximity (< 5Ả) to the key Asp 1132 and Arg 1136 residues,
relative to the parent peptide (Figures 3.4 and 3.5). Specifically, the azapeptide ligand, AcDIazaYET-NH2, 2.36, was found to respectively position the threonine amide and the
aspartate side chain groups near (< 5Ả) the Asp 1132 and Arg 1136 IRTK residues (Figure
3.4). It may be suggested that a combination of hydrogen bonding and ionic interactions were
associated with the azapeptide:IRTK binding model. Moreover, the Ac-DIazaYET-NH2,
2.36, sequence was found to project a turn-type conformation bound to the IRTK domain that
may contribute to binding affinity.
The same grid points were used for the generation of the binding models for the AcDIYET-NH2, 2.28, sequence. The native peptide was positioned further (> 5Ả) from Asp
1132 and Arg 1136 within the catalytic loop of the IRTK (Figure 3.5). Moreover, the parent
pentapeptide was found to project a random conformation at the IRTK binding site. Thus, the
azapeptide ligand Ac-DIazaYET-NH2, 2.36, may confer a stable turn geometry that may
translate into tighter IRTK binding and enhanced inhibitory activity relative to the native
sequence.
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Table 3.1. Binding energy calculations of Ac-DIazaYET-NH2

Figure 3.4. Binding models of the azapeptide Ac-DIazaYET-NH2, 2.36, for the IRTK
binding domain. The spatial distances in between the azapeptide N-terminal Asp and the Cterminal Thr with the IRTK Arg 1136 and Asp 1132 were respectively found at 4.9 and 4.4
Ả.
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Figure 3.5. Binding models of the native pentapeptide Ac-DIYET-NH2, 2.28, for the IRTK
binding domain. The spatial distances in between the peptide N-terminal Asp and the Cterminal Thr with the IRTK Arg 1136 and Asp 1132 were respectively found at 5.4 and 6.5
Ả.

3.4.2

CD SPECTROSCOPY

CD spectroscopy was used to determine the propensity for azapeptides to adopt the putative
β-turn structure which may contribute to enhanced IRTK binding and inhibitory activity. The
main objective of this study was to compare the conformational trends of the parent
pentapeptide sequence, Ac-DIYET-NH2, 2.28, and its related azapeptide analogs. The CD
study was conducted in aqueous conditions (H2O, phosphate buffered saline, PBS) to
determine the influence of salt on peptide conformation. Moreover, the CD spectrum of the
peptides was also collected in DMSO, to support the NMR data acquired for the azapeptides
dissolved in deuterated DMSO. The conformational study of the azapeptides (Table 2.1,
sequence no. 2.37 – 2.42) was used to determine the influence of the aza-substitution on
peptide structure.
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The CD spectra of the peptides were measured on an Aviv 62A DS CD Spectrophotometer
using a 1.0 cm path-length quartz cell containing peptide (20 μM) dissolved in water,
phosphate buffer at pH 7.2 and DMSO at room temperature in the far UV range (190 - 260
nm). The CD spectra were plotted as changes in molar ellipticities (θ) vs. wavelength (nm)
Figures 3.6-3.14.
In order to assess the influence of solvent on peptide structures, the CD spectrum of
the parent peptides Ac-DIYET-NH2, 2.28, and Ac-DIFET-NH2, 2.43, was compared to the
azapeptides (Table 2.1, sequences 2.37 – 2.42). At the 2 position, the [aza-Ile2], [aza-Ala2]
and the [aza-Gly2]-residues exhibited CD spectra that were respectively associated with
random coil in water (Figure 3.6), a combination of helical and turn geometries in phosphate
buffer (Figure 3.7) and folded conformations in DMSO (Figure 3.8).13 Thus, the solvent
conditions were found to impact the azapeptide folds, indicating the influence of solvent and
aza substitutions at the i+1 position on the peptide conformations.
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Figure 3.6. CD spectra for Ac-DazaIYET-NH2, 2.38, Ac-DazaAYET-NH2, 2.37, AcDazaGYET-NH2, 2.39, (20 µM) in water, at 25 °C.
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Figure 3.7. CD spectra for Ac-DazaIYET-NH2, 2.38, Ac-DazaAYET-NH2, 2.37, AcDazaGYET-NH2, 2.39, (20 µM) in phosphate buffer, at 25 °C.
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Figure 3.8. CD spectra for Ac-DazaIYET-NH2, 2.38, Ac-DazaAYET-NH2, 2.37, AcDazaGYET-NH2, 2.39, (20 µM) in DMSO, at 25 °C.
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Moving along to the 3 position of the Ac-DIYET-NH2, 2.28, sequence, [aza-Tyr3], [azaDOPA3] and [aza-Phe3] modifications at the i+2 position were studied by CD spectroscopy
(Figures 3.9-3.11). The CD curve for the parent peptide was typical of a random coil or a
disordered structure, characterized by the strong negative band at 190 nm.13 Conversely, the
CD curve for the azapeptides in water were found to exhibit a change in conformation,
characterized by a positive band near 215 nm and two negative ones near 230 and 190 nm.
The observed structure is indicative of a β-turn geometry, with some proportion of random
coil due to the sharp negative minima observed near 190 nm (Figure 3.9).7,9,10,19,20 The
observed -turn geometry was also maintained for the azapeptide dissolved in phosphate
buffer (Figure 3.10), whereas peptide folds were observed in DMSO (Figure 3.11). Thus, the
insertion of aza-residues at the i+2 position of the native sequence was found to stabilize a
turn conformation about the peptide backbone geometry.
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Figure 3.9. CD spectra for Ac-DIazaYET-NH2, 2.36, Ac-DIazaFET-NH2, 2.40, AcDIaza(DOPA)ET-NH2, 2.41, (20 µM) in water, at 25 °C.
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Figure 3.10. CD spectra for Ac-DIazaYET-NH2, 2.36, Ac-DIazaFET-NH2, 2.40, AcDIaza(DOPA)ET-NH2, 2.41, (20 µM) in phosphate buffer, at 25 °C.
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Figure 3.11. CD spectra for Ac-DIazaYET-NH2, 2.36, Ac-DIazaFET-NH2, 2.40, AcDIaza(DOPA)ET-NH2, 2.41, (20 µM) in DMSO, at 25 °C.
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At the 4 position, Ac-DIYazaET-NH2, 2.42, displayed a CD spectrum in water, PBS
and DMSO that failed to stabilize a peptide turn conformation. These results were based on
the large proportion of random coil observed in water and characterized by the negative
minimum band at 190 nm (Figures 3.12). In phosphate buffer, the azapeptide displayed a
large positive band near 190 nm, that are typically consistent with helical type structures
(Figure 3.13).13 In DMSO, a poorly folded peptide geometry indicated that the aza-Glu
modification at the 4 positon of the sequence weakly stabilized the peptide secondary
structure (Figure 3.14).
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Figure 3.12. CD spectra for Ac-DIYazaET-NH2, 2.42, (20 µM) in water, at 25 °C.
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Figure 3.14. CD spectra for Ac-DIYazaET-NH2, 2.42, (20 µM) in DMSO, at 25 °C.
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In sum, azapeptides (2.36 – 2.42) displayed conformations that were found to vary with the
location and nature of the aza-residue in aqueous media (water and phosphate buffer) and
organic (DMSO) solvents illustrating rich peptide structures that may contribute to biological
activity.
3.4.3

NMR SPECTROSCOPY

NMR spectroscopy was next performed to support the observed azapeptide turn
conformation in Ac-DIazaYET-NH2, 2.36. The NMR spectrum of the parent pentapeptide
Ac-DIYET-NH2, 2.28 was compared to azapeptide, 2.36, in deuterated water and DMSO. In
DMSO, the azapeptide exhibited an NMR spectrum that was consistent with a β-turn
structure. The azapeptide secondary structure was characterized by the disappearance of the
Glu NH and down-field chemical shift of the Ile NH (δ: 8.2 vs 7.6) when compared to the
parent peptide (Figure 3.15 A and B, respectively). This observation is consistent with the
hydrogen bonding interaction found in between the carbonyl group of the Asp residue at the i
position and the amino group of the Glu residue at the i+3 position to generate the turn
conformation that is stabilized by the aza-Tyr residue at the i+2 position. Moreover, 2D
NOESY confirmed successive NOE correlations that were consistent with an organized
azapeptide turn geometry found within Ac-DIazaYET-NH2, 2.36, and absent within AcDIYET-NH2, 2.28, whose protons appeared to be solvent exposed with fewer NOE
correlations (Figure 3.16).20-24
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A

B

Figure 3.15.

1

H NMR spectra of (B) Ac-DIYET-NH2, 2.28, and (A) Ac-DIazaYET-

NH2, 2.36, (2 mM) in DMSO-d6.
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Figure 3.16. 2D NOESY spectrum and conformational analysis of Ac-DIazaYET-NH2,
2.36, (2 mM) in DMSO-d6.
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3.5 CONCLUSIONS
In this chapter a conformational study of the azapeptides (Table 2.1, sequences 2.362.42) belonging to the Ac-DIYET-NH2, 2.28, sequence was conducted to explore the
influence of the aza-substitutions on peptide backbone geometry. A computational study was
initially investigated to determine the molecular structure of a selected azapeptide sequence,
Ac-DIazaYET-NH2, 2.36, and its correlation with IRTK binding. Molecular modeling and
docking studies displayed a folded azapeptide turn geometry which translated into tight IRTK
binding (< 5Å) at the active site of the target receptor. Thus, a -turn conformation was
observed in silico with the Ac-DIazaYET-NH2, 2.36, sequence. In order to validate
azapeptide structures in solution, CD and NMR spectroscopy indicated that the azapeptide
folds were contingent on solvent, location and nature of the aza-residues found within the AcDIYET-NH2, 2.28, sequence. Significantly, aza-substitutions at the i+2 position, Tyr3, were
found to stabilize the -turn structure in water, phosphate buffer and DMSO. Thus, azamodifications at this position may be useful in studying the influence of the -turn trajectory
and side chain interactions on IRTK binding affinity and inhibitory activity. The latter is a
focal point of the biological studies reported in Chapter 4 of this thesis, in order to gain
insight into the SARs in between the putative azapeptide ligands and their IRTK target
receptor.
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3.6
3.6.1

EXPERIMENTAL SECTION
MATERIALS

Sodium chloride, potassium chloride, disodium phosphate, monobasic potassium phosphate
and deuterated solvents were all purchased from Aldrich (Milwaukee, WI) and used without
further purification.
3.6.2

COMPUTATIONAL ANALYSIS

The crystal structure of the IRTK domain (Ser981- Lys1283) bound with ATP and a peptide
ligand (KKKLPATGDYMNMSPVGD) was available for download from the Protein Data
Bank (PDB ID # 1IR3). A molecular docking study was then performed with a selected
azapeptide Ac-DIazaYET-NH2 and compared with the native peptide sequence Ac-DIYETNH2 to visualize the binding model of the peptides on the catalytic loop of the IRTK. An
interface between the molecular graphics system PyMOL and the molecular docking suite
AutoDockVina was used to demonstrate the docking and visualization models. The peptide
ligands were enclosed in a box with the number of grid points in x, y, z directions, 20 x 22 x
16 correlating with a grid spacing of 1.0 Ả. The center of the grid was set to -23.906, 30.439
and 12.466. For the docking simulation studies, the lowest energy docked conformation,
according to the AutoDock scoring function was selected as the binding model.
3.6.3

CD SPECTROSCOPY
The CD spectra of the peptides were collected in the far UV range (190 - 260 nm).

The CD spectra of the peptides were collected and blank corrected with the corresponding
solvent. All CD spectra were recorded on an Aviv 62A DS CD Spectrophotometer using a
1.0 cm path-length quartz cell containing 20 μM of peptide dissolved in water, phosphate
buffer (0.005 M Na2HPO4, 0.14 M KCl and 0.001 M MgCl2 at pH 7.2) and DMSO at room
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temperature. The CD spectra were transported to Microsoft Excel and plotted as changes in
molar ellipticities (θ) vs. wavelength (nm).
3.6.4 NMR SPECTROSCOPY
1

H NMR spectra were recorded on a Varian Oxford NMR spectrometer (500 MHz)

with samples (2 – 5 mM) dissolved in DMSO-d6 and D2O (99.9%) and referenced to H2O
(4.79 ppm) and DMSO-d6 (2.5 ppm). Coupling constants, J values were measured in Hertz
(Hz) and chemical shift values in parts per million (ppm). Two-dimensional COSY, TOCSY
(80 ms mixing time) and NOESY (500 ms mixing time) spectra were acquired at 298 K.
3.6.5 CHARACTERIZATION DATA
Ac-Asp-Ile-azaTyr-Glu-Thr-CONH2 (2.36). Yield (15 mg, 50%), 1H NMR (500 MHz,
DMSO-d6) δ 0.78 (m, 6H), 1.04 (d, J = 6 Hz, 3H), 1.38 (bs, 1H), 1.71 (bs, 1H), 1.82 (s, 3H),
1.84 (m, 1H), 1.96 (m, 1H), 2.25 (m, 2H), 2.44 (dd, J = 8.5, 18 Hz, 1H), 2.63 (dd, J = 5, 20
Hz, 1H), 3.91 (bs, 1H), 4.07 (d, J = 7 Hz, 2H), 4.13 (d, J = 4.5 Hz, 1H), 4.59 (d, J = 6.5 Hz,
1H), 6.67 (d, J = 8.5 Hz, 2H), 7.03 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 14.5 Hz, 2H), 7.50 (bs,
1H), 8.07 (d, J = 6.5 Hz, 1H), 8.16 (s, 1H), 10.2 (bs, 1H); ESI-LCMS [2-90% MeOH in H2O
(0.1% FA), 15 min] RT = 9.95 min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT = 6.68
min; Calculated for C29H42N7O12 [M-H]-,681.3 found m/z 681.2.

Ac-Asp-azaAla-Tyr-Glu-Thr-CONH2 (2.37). Yield (22 mg, 51%), 1H NMR (500 MHz,
D2O) δ 1.21 (m, 1H), 1.27 (d, J = 6 Hz, 3H), 2.04 (m, 1H), 2.08 (s, 3H), 2.15-2.19 (m, 1H),
2.42 (t, J = 7 Hz, 2H), 2.80 (dd, J = 2, 6.25 Hz, 2H), 2.97-3.01 (m, 1H), 3.05 (s, 3H), 3.103.16 (m, 1H), 4.31-4.35 (m, 2H), 4.41-4.74 (m, 2H), 4.60 (t, J = 6 Hz, 1H), 6.88 (d, J = 8.5
Hz, 2H), 7.15 (d, J = 8 Hz, 2H); ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15 min] RT =
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7.42 min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT = 5.26 min; Calculated for
C26H36N7O12 [M-H]-638.3 found m/z 638.2.
Ac-Asp-azaIle-Tyr-Glu-Thr-CONH2 (2.38). Yield (27 mg, 55%), 1H NMR (500 MHz,
D2O) δ 0.67-0.70 (m, 1H), 0.84-0.90 (m, 3H), 0.98-1.10 (m, 3H), 1.27 (dd, J = 2, 6.25 Hz,
3H), 1.40-1.47 (m, 2H), 2.06 (s, 3H), 2.11-2.15 (m, 1H), 2.39 (t, J = 5 Hz, 2H), 2.68-2.86 (m,
2H), 2.97-3.02 (m, 1H), 3.06-3.10 (m, 1H), 3.19-3.26 (m, 1H), 4.29-4.36 (m, 3H), 4.41-4.43
(m, 1H), 4.54-4.48 (m, 1H), 4.57-4.60 (m, 1H), 6.86-6.91 (m, 2H), 7.13 (d, J = 8.5 Hz, 1H),
7.22 (d, J = 8 Hz, 1H); ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15 min] RT = 6.97
min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT = 5.13 min; Calculated for C29H42N7O12
[M-H]-680.3 found m/z 680.2.
Ac-Asp-azaGly-Tyr-Glu-Thr-CONH2 (2.39). Yield (22 mg, 55%), 1H NMR (500 MHz,
D2O) δ 1.27 (d, J = 6 Hz, 3H), 2.00-2.06 (m, 2H), 2.08 (s, 3H), 2.14-2.18 (m, 1H), 2.36-2.39
(m, 2H), 2.75 (dd, J = 2.5, 6.5 Hz 2H), 3.01 (dd, J = 8.5, 14 Hz, 1H), 3.12 (dd, J = 6, 14.5 Hz,
1H), 4.30-4.34 (m, 2H), 4.41 (dd, J = 5, 9.25 Hz, 1H), 4.49 (dd, J = 6, 8.5 Hz, 1H), 4.65 (t, J
= 6.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 7.17 (d, J = 8.5, 2H); ESI-LCMS [2-90% MeOH in
H2O (0.1% FA), 15 min] RT = 6.99 min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT =
5.04 min; Calculated for C25H34N7O12 [M-H]- 624.2 found m/z 624.2.
Ac-Asp-Ile-azaPhe-Glu-Thr-CONH2 (2.40). Yield (17 mg, 43%), 1H NMR (500 MHz,
D2O) δ 0.85 (m, 6H), 1.13 (m, 1H), 1.29 (d, J = 6.5 Hz, 3H), 1.35 (bs, 1H), 1.84 (bs, 1H),
2.05 (s, 3H), 2.18 (m, 1H), 2.39 (bs, 2H), 2.58 (dd, J = 8, 16.5 Hz, 1H), 2.69 (dd, J = 6.5, 16
Hz, 1H), 4.05 (bs, 1H), 4.34-4.39 (m, 3H), 4.63-6.65 (m, 1H), 7.37 (d, J = 7.5 Hz, 2H), 7.417.47 (m, 3H); ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15 min] RT = 11.76 min; [2-
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90% MeCN in H2O (0.1% FA), 15 min] RT = 7.78 min; Calculated for C29H44N7O11 [M+H]+,
666.3 found m/z 666.2.
Ac-Asp-Ile-aza(DOPA)-Glu-Thr-CONH2 (2.41). Yield (6 mg, 36%), 1H NMR (500 MHz,
D2O) δ 0.82-0.89 (m, 6H), 1.06 (bs, 1H), 1.28 (d, J = 6.5 Hz, 3H), 1.82 (bs, 1H), 2.05 (s, 6H),
2.16 (bs, 2H), 2.31 (bs, 2H), 2.58 (bs, 1H), 2.67-2.70 (m, 1H), 4.05 (bs, 1H), 4.31-4.38 (m,
4H), 4.63-4.67 (m, 2H), 6.62-6.65 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 6.88 (s, 1H), 6.92 (d, J =
8 Hz, 1H); ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15 min] RT = 8.90 min; [2-90%
MeCN in H2O (0.1% FA), 15 min] RT = 6.33 min; Calculated for C29H44N7O13
[M+H]+,698.3 found m/z 698.2.
Ac-Asp-Ile-Tyr-azaGlu-Thr-CONH2 (2.42). Yield (16 mg, 42%), 1H NMR (500 MHz,
D2O) δ 0.81-0.86 (m, 1H), 0.89-0.96 (m, 6H), 1.22 (d, J = 7 Hz, 3H), 1.47 (bs, 1H), 1.85-1.88
(m, 1H), 2.07 (s, 3H), 2.57 (dd, J = 9, 16 Hz, 1H), 2.70 (dd, J = 5.5, 16 Hz, 1H), 3.00 (m,
2H), 3.25 (dd, J = 6, 13 Hz, 1H), 3.66 (bs, 1H), 4.20 (d, J = 4 Hz, 1H), 4.23 (d, J = 8 Hz, 1H),
4.30 (t, J = 4 Hz, 1H), 4.41 (bs, 1H), 4.61 (dd, J = 5.5, 8.5 Hz, 1H) 6.91 (d, J = 8.5 Hz, 2H),
7.24 (d, J = 8 Hz, 2H); ESI-LCMS [2-90% MeOH in H2O (0.1% FA), 15 min] RT = 9.61
min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT = 6.41 min; Calculated for C29H42N7O12
[M-H]-, 680.3 found m/z 680.2.
Ac-Asp-Ile-Tyr-Glu-Thr-CONH2 (2.28). Yield (50 mg, 75%), 1H NMR (500 MHz, DMSOd6) δ 0.60-0.67 (m, 6H), 0.85-0.91 (m, 1H), 0.96 (d, J = 6.5 Hz, 3H), 1.07 (bs, 1H), 1.58-1.61
(m, 1H), 1.71-1.74 (m, 1H), 1.76 (s, 3H), 1.89 (bs, 1H), 2.15-2.23 (m, 2H), 2.37-2.40 (m,
1H), 2.54-2.59 (m, 1H), 2.68 (bs, 1H), 2.86 (dd, J = 4, 14 Hz, 1H), 3.94-3.97 (m, 1H), 3.994.01 (m, 1H), 4.23 (dd, J = 8.5, 13 Hz, 1H), 4.34 (bs, 1H), 4.53 (dd, J = 7.5, 14 Hz, 1H), 4.77
(bs, 1H), 6.43 (bs, 1H), 6.55-6.57 (m, 2H), 6.95-7.01 (m, 4H), 7.45 (d, J = 8.5 Hz, 1H), 7.63
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(bs, 1H), 7.90 (bs, 1H), 8.09 (bs, 1H), 9.04 (bs, 1H); ESI-LCMS [2-90% MeOH in H2O
(0.1% FA), 15 min] RT = 9.34 min; [2-90% MeCN in H2O (0.1% FA), 15 min] RT = 6.55
min; Calculated for C30H45N6O12 [M+H]+,681.3 found m/z 681.2.
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3.7
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CHAPTER 4. IRTK INHIBITORY ACTIVITY OF AZAPEPTIDES

4.1

ABSTRACT

In the absence of regulated tyrosine kinase activity of the insulin receptor, increased levels
of gene expression and cell proliferation have been observed and associated with tumor
progression. Thus, the inhibition of un-regulated tyrosine kinase phosphorylation of the
insulin receptor may prove to be an effective form of cancer treatment. Towards this goal,
synthetic pentapeptides, Ac-DIYET-NH2 (2.28) derived from the activation loop of the
insulin receptor and related analog, Ac-DIFET-NH2 (2.43), were found to inhibit the
autophosphorylation of the insulin receptor to about 80% and 20%, respectively, at 4 mM
making them potential leads in the development of novel peptide-based anti-cancer drugs.
Moreover, molecular docking simulation studies of the lead peptide ligand, 2.28, bound
within the active site of the IRTK revealed a folded peptide structure, reminiscent of a turn
geometry that may contribute to binding affinity with its receptor target. In order to test this
hypothesis, azapeptide derivatives of the Ac-DIYET-NH2 sequence, and specifically
encompassing aza-modifications within the IYE region were developed for structure activity
relationship studies. CD and NMR spectroscopy proved that the Ac-DIazaYET-NH2
sequence, 2.36, adopted a β-turn conformation. In this chapter, the phosphorylation activity
of the recombinant IRTK domain (residues 1005-1310) in the presence of ATP (1000 µM)
was initially validated by western blotting. The inhibitory activity of the peptides, AcDIYET-NH2 (2.28) vs Ac-DIazaYET-NH2 (2.36), was next evaluated by conducting the
IRTK phosphorylation reactions with the addition of peptide ligands (400 µM). In a single
dose experiment, minimal inhibitory activity (<10%) was detected for the parent peptide, Ac-
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DIYET-NH2 (2.28), whereas, Ac-DIazaYET-NH2 (2.36) displayed 50% inhibition of the
IRTK autophosphorylation. The azapeptide analogs, DazaIYET, DazaGYET and DazaAYET
exhibited about 25% - 40% inhibition of the IRTK phosphorylation at 400 µM concentration.
The azapeptide analogs, [aza-DOPA3] and [aza-Glu4] displayed slight stimulatory effect on
the phosphorylation activity of the IRTK at similar concentration levels.
These results validate the importance of the peptide-turn geometry on the inhibition of
IRTK phosphorylation. This finding is not only important towards the development of potent
azapeptide inhibitors of the IRTK for potential anti-cancer applications, but also in the design
of novel peptide ligands that may function as useful probes for studying the mechanisms and
kinetics associated with this important class of tyrosine kinases.

4.2

INTRODUCTION

4.2.1. SIGNALING ACTIVITIES OF THE RECEPTOR TYROSINE KINASES
Signal transduction is ubiquitous in all cell types and involves the transfer of
information from within and in between cells in order to regulate their structure and function.
Signaling activity is transmitted from a ligand to a protein receptor and converted into a
cellular response, which in turn regulates a biochemical process such as metabolism. Signal
transduction must be precisely integrated and coordinated for normal cell function. The
human genome project has revealed that ~ 20% of the ~ 32,000 human coding genes encode
proteins that are implicated in signal transduction.1 These include the transmembrane Gcoupled protein receptors, whose recently solved crystal structures have led to a better
understanding of their signaling activities.2 A Nobel Prize was recently awarded to Drs.
Robert Lefkowitz and Brian Kobilka in 2012 for their contributions into the structure and
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function of this important class of signaling receptors.3 Within this class of G-coupled protein
receptors, more than 520 protein kinases and 130 protein phosphatases have been implicated
in cell signaling activity by regulating protein phosphorylation.4 The protein kinases govern
substrate phosphorylation with ATP, and are further divided into subgroups which define
their target phosphorylation sites. The protein or receptor tyrosine kinases, PTK or RTK,
respectively, promote substrate-level phosphorylation onto active site tyrosine residues,
whereas the serine/threonine specific enzymes phosphorylate active site serine and threonine
residues. The phosphorylation activity of kinases has crucial cellular effects. These are most
often implicated with the activation of signaling pathways that control gene expression,
protein production and function in addition to regulating cell metabolism which governs the
cell cycle for proliferation. Thus, PTKs are among the most widely studied classes of
enzymes for their important implications in regulated and oncogenic signaling.5
4.2.2. THE INSULIN RECEPTOR TYROSINE KINASE
The RTKs encompass a large family of membrane bound protein receptors with
intrinsic phosphorylation signaling activity.6 Insulin receptor has associated RTK activity
found within its cytoplasmic domain. The insulin receptor tyrosine kinase (IRTK) is a
heterotetrameric transmembrane protein having two identical extracellular α-subunits that
function as the binding site for the natural ligand insulin and intracellular β-subunits which
encompass the RTK domain (Figure 4.1).7 Signal transduction of the IRTK is mediated by
insulin binding to the extracellular α-subunit of the IRTK. This ligand:receptor binding
interaction produces conformational changes within the cytosolic β-subunits, exposing the
RTK for ATP binding and phosphorylation onto the active site tyrosine residues.7,8 There are
3 major phosphorylation sites found within the insulin receptor (Figure 4.2) including a juxta
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membrane region having Tyr residues, 965 and 979, the activation loop at position, 1158,
1162 and 1163 and the C-terminal region at 1328 and 1334.9

Figure

4.1.

Figurative

description

of

the

IRTK.

Figure

adapted

from:

http://grimwade.biochem.unimelb.edu.au/tutorial/s2730e.gif

Figure 4.2.

Phosphorylation sites of the IRTK. Figure adapted from: Hirose, M. et al. Br. J.

Pharm. 2004, 142, 222 -228.16
This ligand:receptor binding interaction causes a change in IRTK conformation which
subsequently leads to phosphorylation of the key tyrosine residues in the activation loop,
Tyr1158, Tyr1162, Tyr1163 in the presence of ATP.7-9 Once these tyrosine residues are
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phosphorylated, an additional conformational change occurs within the activation loop of the
IRTK for additional phosphorylation which activates the receptor for intracellular signaling
activity.7-9 The activated IRTK then dictates a myriad of signaling events, such as the PI(3)K,
CAP/CbI and the Ras/MAPK pathways, respectively associated with glucose metabolism,
protein synthesis, and cell proliferation.10-12
In order to maintain regulated IRTK signal transduction, the kinase activities of the
RTKs must be precisely controlled. For example, when the receptor is in its inactive state the
activation loop of the IRTK binds to its catalytic loop and inhibits the kinase domain by
preventing ATP binding and phosphorylation of the active site Tyr residues.9 This
conformation is stabilized by the hydrogen bonding interactions in between the Tyr 1162
residue in the activation loop of the insulin receptor and the Asp1132 residue in the catalytic
loop of the RTK. Binding of insulin to the α-subunit reverses this process and activates
tyrosine specific phosphotransferase activity with ATP. This leads to the autophosphorylation
of the specific tyrosine residues in the cytoplasmic domain of the β-subunit. The
phosphorylation of the Tyr 1158 Tyr 1162 and Tyr1163 residues is mainly responsible for
activation of substrate phosphorylation.9 The introduction of three anionic phosphotyrosine
residues forces a 30 Å change in the position of the activation loop away from the substrate
binding site, making it available to bind to and phosphorylate a target protein as shown in
Figure 4.3.13
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Figure 4.3. Phosphorylation mechanism of the IRTK. Figure adapted from: Nelson, D.L.;
Cox, M.M. Lehninger Principles of Biochemistry 5 ed., 2008, W.H. Freeman and Co. New
York, NY, 440.13
Among the most important IRTK signal transduction pathways, the mitogen-activated
protein, MAP kinase signaling cascade regulates gene expression and cell proliferation.12,13
This signaling pathway is triggered by insulin binding to the -subunit of the IRTK leading
to a series of substrate-level phosphorylation reactions which activates proteins that
ultimately cause gene expression in the cells’ nucleus (Figure 4.4). Initially, the
phosphorylated IRTK stimulates phosphorylation and activation of the insulin receptor
substrate 1, IRS-1, which in turn phosphorylates the growth factor receptor-bound protein,
Grb2. Then the guanine nucleotide exchange factor, Sos binds to phosphorylated Grb2 and
the Ras protein causing GTP binding to Ras and GDP release. Activated Ras then binds to
Raf-1 and activates the so-called proto-oncogene serine/threonine protein kinase to
phosphorylate the MEK serine residues. Activated MEK phosphorylates ERK which enters
the nucleus and phosphorylates nuclear transcription factors Elk1 and SRF which stimulates
mRNA transcription, protein translation and cell division.
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Figure 4.4 MAP kinase signaling cascade. Figure adapted from: Nelson, D.L.; Cox, M.M.
Lehninger Principles of Biochemistry 5 ed., 2008, W.H. Freeman and Co. New York, NY,
440.13
Normal IRTK MAP kinase signaling activity is found in epithelial cells that are expressed
at lower basal levels.6 Unregulated IRTK MAP kinase signaling activity has been associated
with uncontrolled gene expression, protein production and cell proliferation that are
hallmarks of tumor growth.5 The overexpression and aberrant signaling activity of the IRTK
have been found to occur in human breast, ovarian, colon and other epithelial tumors.14 It has
been found that the IRTK may be directly related to oncogenic signaling activity by affecting
cell metabolism and/or by working in synergy with other oncogenes that effect cell growth
and differentiation. Moreover, genomic rearrangements such as chromosomal translocations,
gain-of-function, GOF mutations, small deletions in PTKs, and gene amplification may each
trigger oncogenic kinase signaling.5
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4.2.3. INHIBITION OF IRTK PHOSPHORYLATION BY THE DIYET SEQUENCE
Considering their relevance in cancer, the selective regulation and potent inhibition of
aberrant IRTK signaling activity may form the basis for effective forms of cancer treatment.15
Towards this goal, the pentapeptide, Ac-DIYET-NH2 (2.28), derived from the activation loop
of the IRTK (G1149DFGMTRDIY1158ETDY1162Y1163RKGGKGL1170) and specifically
encompassing the autophosphorylation site (Y1158) was found to inhibit IRTK
phosphorylation to about 80% at 4 mM.16,17 Moreover, competitive binding experiments in
between ATP and Ac-DIYET-NH2 (2.28) demonstrated that the pentapeptide was a
competitive inhibitor of the IRTK domain, binding to the catalytic loop of the receptor and
thereby preventing autophosphorylation of the IRTK in a non-ATP dependent manner.17 This
mechanism was also confirmed by mass spectrometry, which indicated that the Ac-DIYETNH2 (2.28) sequence was phosphorylated at the tyrosine residue by the IRTK. Other peptide
ligands were developed, of which Ac-DIFET-NH2 (2.43), demonstrated modest inhibition
(20% at 4 mM) illustrating the importance of the Tyr side chain on peptide activity.
Moreover, molecular docking simulation studies in between the Ac-DIYET-NH2 (2.28)
sequence and the IRTK demonstrated a folded peptide geometry, which resembled a -turn
motif. These studies suggested that a peptide turn may be also responsible for IRTK binding
and inhibitory activity. Thus, peptide mimics (peptidomimetics) that may stabilize the
putative bio-active -turn conformation responsible for IRTK binding may lead to the
generation of more potent IRTK inhibitors. Towards this goal, azapeptide analogs of the
parent pentapeptide Ac-DIYET-NH2 (2.28) were synthesized by submonomer solid-phase
synthesis to explore the importance of a turn conformation on IRTK inhibitory activity.
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4.3. CHAPTER OBJECTIVES
The biological activity of the peptides synthesized in Chapter 2 and characterized in
Chapter 3 will be described in this chapter. More specifically, the azapeptide derivatives of
the

Ac-DIYET-NH2

(2.28)

sequence

will

be

tested

as

inhibitors

of

IRTK

autophosphorylation. The western blotting technique will be employed to determine the
peptides’ ability to inhibit IRTK phosphorylation. Briefly, the IRTK and ATP will be
incubated with and without the peptides to determine their influence on IRTK
phosphorylation. Following the IRTK phosphorylation reactions, the protein samples will be
separated on by PAGE and the phosphorylated IRTK will be selected by a primary antibody
which only binds to the phosphorylated form of the IRTK. A secondary antibody coupled
with a detection probe is finally added to monitor the signal. In this manner, the effect of the
peptides on IRTK phosphorylation can be tracked and evaluated quantitatively by
densiometric analyses. This study will serve to validate the assumption that a biologically
active turn conformation within the parent Ac-DIYET-NH2 (2.28) sequence is responsible for
IRTK binding and inhibition of phosphorylation in the presence of ATP. Azapeptides are
perfectly suitable probes for testing the influence of turn conformations on peptide activity as
the semicarbazide modification is known to restrain the ψ and φ dihedral angles leading to
some types of β-turn conformations. Thus, azapeptide derivatives of the Ac-DIYET-NH2
(2.28) sequence will be tested as potential inhibitors of IRTK phosphorylation en route
towards the development of peptide-based anti-cancer agents (Figure 2.5).
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4.4.

RESULTS AND DISCUSSION

4.4.1 IRTK PHOSPHORYLATION STUDIES
A preliminary study on the inhibitory activity of the azapeptide Ac-DIazaYET-NH2 (2.36)
in comparison with the native sequence Ac-DIYET-NH2 (2.28) was performed by western
blot. The phosphorylation activity of the recombinant IRTK domain (residues 1005-1310)
was initially determined with the IRTK (200 ng/mL) (Figure 4.5, lane 1), the IRTK (200
ng/mL) and ATP (1000 µM) (Figure 4.5, lane 2), and with the IRTK (200 ng/mL), ATP
(1000 µM) and insulin (200 ng/mL) (Figure 4.5, lane 3), in a reaction buffer consisting of
HEPES, NaCl, EDTA, MgCl2, MnCl2, DTT, and phenylmethylsufonyl fluoride.
The phosphorylation reactions were performed in Eppendorf tubes at 37 ºC for 20 minutes.
The reactions were then quenched (Laemmli sample buffer) and heated at 70 ºC for 10
minutes prior to gel electrophoresis. The samples were then resolved by denaturing 10% BisTris PAGE and transferred to a PVDF membrane in a transfer buffer (25 mM Bicine, 25 mM
Bis-Tris (free base, 1 mM EDTA, pH 7.2) at 30 V for 1 hour. The membrane was kept for
overnight blocking in bovine serum albumin and Tris-buffered saline with Tween 20 (2%
BSA in TBST) to prevent any non-specific binding. The membrane was then rinsed and
treated with primary antibody, antiphospho-IR/IGFIR (Tyr 1158, 1162, 1163). The antigen–
antibody complexes were then visualized with a goat anti-rabbit IgG antibody, alkaline
phosphatase (AP) conjugate which catalyzed the colorimetric detection of the blue colored
phosphorylated IRTK using 5-Bromo-4-chloro-3-indolyl phosphate/ Nitroblue tetrazolium
(BCIP/NBT). The combination of NBT (nitro-blue tetrazolium chloride) and BCIP (5-bromo4-chloro-3'-indolyphosphate p-toluidine salt) yields an intense, insoluble black-purple
precipitate when reacted with alkaline phosphatase (Scheme 4.1).18
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Scheme 4.1. Reaction mechanism for color development using BCIP/NBT.18
The substrate BCIP, 4.1, is hydrolyzed by alkaline phosphatase to form an intermediate
that undergoes dimerization to produce an indigo dye, 4.4. The NBT is reduced to the NBTformazan during the oxidation of 4.3 to 4.4. This reaction proceeds at a steady rate, allowing
for accurate control of detection during the reaction progress. The signal intensity may be
then

measured

by

densiometric

analyses

using

Image

J

(http://rsbweb.nih.gov/ij/download.html).
Incubation of IRTK in a HEPES buffer without ATP did not produce any visible bands
following immunoblotting (Figure 4.5, lane 1). This is an expected result, considering in the
absence of ATP no IRTK phosphorylation can occur nor can be detected by the primary
antibody used for binding phosphorylated IRTK. A band was observed when the IRTK was
phosphorylated with ATP (Figure 4.5, lane 2) and a more intense signal, albeit with a modest
increase of ~10% relative to the control IRTK + ATP sample was observed with additional
insulin (Figure 4.5, lane 3). The latter result is somewhat surprising, since only a small
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portion of the IRTK (residues 1005-1310) comprising the cytoplasmic -subunit of the RTK
domain and not the extracellular -subunit insulin binding site was used for this study. These
results suggests the presence of an allosteric binding pocket on the IRTK domain that may
contribute towards insulin binding and activation of IRTK phosphorylation. This result may
be noteworthy of further investigation, but falls outside the scope of this present study.
Therefore, further analyses were performed without the addition of insulin.

Figure 4.5. Western blot analyses of the IRTK phosphorylation activity. Samples were
analyzed as: IRTK (200 ng/mL) (lane 1), IRTK (200 ng/mL) and ATP (1000 µM) (lane 2),
and with the IRTK (200 ng/mL), ATP (1000 µM) and insulin (200 ng/mL) (lane 3), in a
HEPES reaction buffer consisting of HEPES, NaCl, EDTA, MgCl2, MnCl2, DTT, and
phenylmethylsufonyl fluoride.
4.4.2 INHIBITION OF IRTK PHOSHORYLATION
The inhibitory activity of the peptides, Ac-DIYET-NH2 (2.28) vs Ac-DIazaYET-NH2
(2.36), was next evaluated by conducting the IRTK phosphorylation reactions as previously
described, but with the addition of peptide ligands (400 µM). Phosphorylation of the insulin
receptor in the absence of the peptide ligands was considered to be 100%. In this single dose
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experiment, minimal inhibitory activity (<10%) was detected for the parent peptide, AcDIYET-NH2 (2.28), whereas, Ac-DIazaYET-NH2 (2.36) displayed about 50% inhibition of
the IRTK autophosphorylation (Figure 4.6). This result lends supporting evidence that the βturn conformation adopted by the selected azapeptide, Ac-DIazaYET-NH2 (2.36) may
contribute to IRTK binding affinity and inhibitory activity within the catalytic loop of the
RTK active site.

Figure 4.6. Western blot data for IRTK (200 ng/mL) phosphorylation inhibition with peptide
ligands Ac- DIYET-NH2 (2.28), and Ac-DIazaYET-NH2 (2.36) at 400 M. Each experiment
was conducted in replicate n=3 with standard deviations reported about the mean % IRTK
phosphorylation.
A dose-response (0 - 400 µM) assay was next conducted, comparing the inhibitory activity
of the native sequence (2.28) with the azapeptide (2.36) and a known tyrphostin (AG1024)
inhibitor of the IRTK was used as control.19 Three different concentrations of peptide ligands,
4, 40 and 400 µM were used for this dose-response assay (Figure 4.7). In this experiment,
Ac-DIazaYET-NH2 (2.36), maintained about 50% inhibitory activity of the IRTK
autophosphorylation at 400 µM, albeit to a lesser extent relative to the tyrphostin inhibitor
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(~80% inhibition at 40 µM) and without a dose-response correlation as depicted below. No
significant inhibitory activity was noticed for the natural sequence with the conditions used in
this study and which differ from the literature reported conditions, especially with the use of
the IRTK.16,17

Figure 4.7. Western blot data for IRTK (200 ng/mL) phosphorylation inhibition with peptide
ligands Ac-DIYET-NH2 (2.28), and Ac-DIazaYET-NH2 (2.36) in addition to tyrphostin
inhibitor (AG1024) at 4, 40 and 400 M. Each experiment was conducted in replicate n=3
with standard deviations reported about the mean % IRTK phosphorylation.
The inhibitory activity of the azapeptides on IRTK autophosphorylation was tested at
400 µM by western blot. A control sample consisting of the IRTK (200 ng) and ATP (1000
µM) was included in the phosphorylation reaction without the addition of any peptides and
considered as 100% phosphorylation. The experimental results showed that the inhibitory
activity of the azapeptides vary on the position and composition of the aza-residue. In this
library, the Ac-DIazaYET-NH2 sequence exhibited the most antagonistic activity (50-60%)
on the autophosphorylation of the IRTK. Similarly, the azapeptide analogs DazaAYET,
DazaGYET and DazaIYET showed about 25% - 40 % inhibitory activity on the
autophosphorylation of IRTK. Conversely, the azapeptide analog [azaDOPA3] displayed an
increase (30%) in the autophosphorylation activity of IRTK. A similar effect was also
observed for the azapeptide analog [azaE4], with a modest (10%) increase in IRTK
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autophosphorylation activity. The modulatory effects of the azapeptide ligands on IRTK
autophosphorylation are depicted in Figure 4.8.

Figure 4.8. Western blot data for IRTK (200 ng/mL) phosphorylation inhibition with peptide
ligands synthesized in this study at 400 M. Each experiment was conducted in replicate n=3
with standard deviations reported about the mean % IRTK phosphorylation.
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Entry
1

2
3
4
5
6
7
8
9

Sequence (#)
Ac-DIYET-NH2 (2.28)
Ac-DIFET-NH2 (2.43)
Ac-DIazaYET-NH2 (2.36)
Ac-DIazaFET-NH2 (2.40)
Ac-DIaza(DOPA)ET-NH2 (2.41)
Ac-DIYazaET-NH2 (2.42)
Ac-DazaAYET-NH2(2.37)
Ac-DazaGYET-NH2 (2.39)
Ac-DazaIYET-NH2 (2.38)

% IRTK
Phosphorylation
82 ± 12
84 ± 5.7
40 ± 8.2
67 ± 9.4
128 ± 2.9
110 ± 3.6
74 ± 19
61 ± 2.3
73 ± 10

Table 4.1 IRTK Phosphorylation (%) in presence of peptides (400 µM) and ATP (1000 µM)

4.5 CONCLUSIONS
In sum, a new class of azapeptide inhibitors of the IRTK domain have been validated in
this study. The selected azapeptide, Ac-DIazaYET-NH2 (2.36), which demonstrated a stable
β-turn geometry resulted in a ~5-fold increase in IRTK inhibitory activity relative to the
parent pentapeptide (50 vs <10%). The azapeptide analogs, Ac-DazaIYET-NH2 (2.38), and
Ac-DazaAYET-NH2 (2.37) exhibited about 25% and Ac-DazaGYET-NH2 (2.39) exhibited
about 40% inhibitory activity on the autophosphorylation of IRTK.

Thus, azapeptide

inhibitors of the IRTK may form new leads in the development of potent and selective Tyr
kinase binding ligands for anti-cancer20 and related applications in drug discovery.15
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4.7 EXPERIMENTAL MEHODS
4.7.1. Materials and Methods
The insulin receptor tyrosine kinase domain, IRTK, (EMD Millipore, cat. no. 14-466)
ATP (sigma) and insulin (calbiochem) were used directly as received. The reagents for
preparing the reaction buffer, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, HEPES,
(Sigma), NaCl (Macron), ethylenediaminetetraacetic acid, EDTA, (Sigma), MgCl2 (Fisher),
MnCl2 (Fisher), dithiothreitol, DTT, (BRL) and phenylmethylsufonyl fluoride (sigma aldrich)
were mixed together in MilliQ grade water and adjusted at pH 7.4. Laemmli sample buffer
(consisting of 106 mM Tris HCl, 141 mM Tris Base, 2% LDS, 10% Glycerol, 0.51 mM
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EDTA, 0.22 mM SERVA Blue G250, 0.175 mM Phenol Red, pH 8.5) was purchased from
(Life Technologies) and used to quench the phosphorylation reactions prior to PAGE and
western blotting. The gels, 10% Bis-Tris PAGE were purchased from Life Technologies and
transferred to a polyvinylidene fluoride, PVDF, membrane (Millipore) for immunoblotting.
Bovine serum albumin in tris-buffered saline containing 20% Tween 20 (2% BSA in TBST)
was purchased from GeneTex and used directly for membrane blocking. The antibodies for
phosphor-IRTK detection antiphospho-IR/IGFIR (Tyr1158/Tyr 1162/Tyr 1163) (EMD
Millipore, cat. no. 07-841) and goat anti-rabbit IgG antibody, Alkaline Phosphatase conjugate
(EMD Millipore, cat. no. 12-448) were used directly as received. The colorimetric detection
of the antigen:antibody complexes was determined using 5-Bromo-4-chloro-3-indolyl
phosphate / Nitroblue tetrazolium (BCIP/NBT) purchased from Sigma Aldrich. The IRTK
inhibitor, AG1024 (EMD Millipore, cat. no. 121767) was also used as a control inhibitor for
the IRTK.
4.7.2 Phosphorylation reactions of the IRTK
The phosphorylation of the active insulin receptor tyrosine kinase domain, IRTK,
encompassing residues 1005-1310 (EMD Millipore, cat. no. 14-466) was initially performed
by treating the IRTK (200 ng) with ATP (1000 µM) and insulin (2.6 µg/mL) in 25 µL of
incubation buffer consisting of 50 mM HEPES pH 7.4, 125 mM NaCl, 1 mM EDTA, 10 mM
MgCl2, 5 mM MnCl2, 5 mM DTT and 1 mM phenylmethylsufonyl fluoride for 20 min at 37
o

C. The reaction was quenched by addition of Laemmli sample buffer (8 µL) and the IRTK

was denatured at 70 ºC for 10 minutes followed by separation and detection by western
blotting.
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4.7.3. Inhibition studies of the IRTK
The inhibitory activity of the peptides on the autophosphorylation of the insulin receptor
was next evaluated by adding various concentrations (4-400 µM) of the peptides or control
IRTK inhibitor, AG1024 (EMD Millipore, cat. no. 121767) to the IRTK (200 ng) and then
proceeding with the phosphorylation reactions as previously described. The reactions were
quenched by the addition of Laemmli sample buffer (8 µL) and the IRTK was denatured at
70 ºC for 10 minutes and analyzed by western blotting.
4.7.4. Western blotting
The IRTK was then resolved by denaturing 10% Bis-Tris PAGE and transferred to a
PVDF membrane for overnight blocking (2% BSA in TBST) and immunoblotting was
performed with antiphospho-IR/IGFIR (Tyr1158/Tyr 1162/Tyr 1163). The antigen–antibody
complexes were visualized with a goat anti-rabbit IgG antibody, Alkaline Phosphatase
conjugate (EMD Millipore, cat. no. 12-448) which catalyzed the colorimetric detection of the
complexes

using

5-Bromo-4-chloro-3-indolyl

phosphate

/

Nitroblue

tetrazolium

(BCIP/NBT). After addition of the color development solution (BCIP/NBT) the reaction was
continued for 10 minutes to visualize the desired bands. The PVDF membrane was rinsed
with deionized water and dried at room temperature. The band intensities were measured by
Image J (http://rsbweb.nih.gov/ij/download.html). The autophosphorylation of the IRTK
domain in the presence of 1000 µM ATP for 20 minutes at 37 ºC was taken as control and
considered to be 100%. A commercially available IRTK inhibitor, AG1024 (EMD Millipore,
cat. no. 121767) was also used as a control inhibitor for the IRTK.
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CHAPTER 5: CONCLUSIONS AND CONTRIBUTIONS TO
KNOWLEDGE
5.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS
THESIS

5.1.1

DESIGN,

SYNTHESIS

AND

CONFORMATIONAL

ANALYSES

OF

AZAPEPTIDE INHIBITORS OF THE INSULIN RECEPTOR TYROSINE KINASE
Receptor tyrosine kinases play a crucial role in cell growth and differentiation. The
phosphorylation activity of kinases is implicated in the activation of signaling pathways that
governs the cell cycle for proliferation among other biological functions. Thus, kinase
signaling activity must be highly regulated in order to maintain cellular homeostasis and
avoid tumorogenesis. In cells that harbor mutations or genetic modifications leading to the
overexpression of receptor tyrosine kinases, regulated cell division ceases to exist lending
rise to cell division without restriction. As a result, the overexpression of receptor tyrosine
kinases has been associated with oncogenic signaling and the growth of tumors. They have
been vastly implicated in many epithelial tumor types, such as those belonging to breast,
ovarian and prostate cancers. Thus, the selective inhibition of aberrant receptor tyrosine
kinase signaling activity may lead to the development of effective forms of cancer therapy.
Towards this goal, a synthetic pentapeptide, Ac-DIYET-NH2, derived from the activation
loop of the insulin receptor tyrosine kinase (IRTK) domain has been validated as a peptide
lead for the inhibition of IRTK phosphorylation and activation of its signaling activity. The
peptide sequence exhibited strong IRTK inhibition (~80%), albeit at high concentration levels
(4 mM) which limits its applications in vivo. Moreover, molecular docking studies of the lead
pentapeptide bound to the active site of the IRTK domain demonstrated a turn type peptide
geometry that may contribute to binding affinity and inhibitory activity. Considering
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azapeptides are a valid class of peptide mimics that are known to stabilize bio-active turn
conformations, a small library (7) of azapeptide analogs of the Ac-DIYET-NH2 sequence
were synthesized, characterized and evaluated for IRTK inhibitory activity.
A submonomer approach was adopted for the synthesis of azapeptides belonging to
the Ac-DIYET-NH2 sequence in order to systematically introduce aza-residues within the
IYE pharmacophoric region of the peptide sequence. In Chapter 2, the submonomer solid
phase synthesis furnished a small library (7) of azapeptides featuring the introduction of new
aza-Ile and aza-DOPA residues. Halogen exchange reactions were found to be particularly
useful for the introduction of aza-Tyr and aza-DOPA residues at the Tyr3 position. These
reactions were used to convert the poorly reactive benzyl chlorides to the more reactive
iodides leading to azapeptides, 2.36 and 2.41 in 50 and 36% yields, respectively. The azaisoleucine analog was synthesized using racemic 2-iodobutane as alkylating agent in the
presence of BTPP. Although this resulted in diastereomeric Ac-DazaIYET-NH2, 2.38, RPLCMS purification and analysis provided a single diastereomer, suitable for SAR studies.
Azapeptides were isolated in sufficient yields (36-55%) and good purities (>95%) following
submonomer synthesis and RP-LCMS purification. Thus, the submonomer approach for
azapeptide synthesis proved to be an efficient method for the preparation of azapeptides
useful for structure-function studies as described in Chapters 3 and 4.
A conformational analysis of the novel azapeptides synthesized in Chapter 2 was
presented in Chapter 3 of this thesis. A molecular docking simulation study was initially
performed to evaluate the propensity for the azapeptide analog Ac-DIazaYET-NH2, 2.36, to
adopt a turn geometry at the active site of the IRTK. An interface between the molecular
graphics system PyMOL and the molecular docking suite AutoDock Vina was used to
demonstrate the combination of docking and visualization models. The Ac-DIazaYET-NH2,
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2.36, sequence was found to be in close proximity to the key IRTK binding site residues Asp
1132 and Arg 1136 found within the catalytic loop of the IRTK. Moreover, the azapeptide
was found to project a turn-type conformation bound to the IRTK domain that may contribute
to binding affinity. CD and NMR spectroscopy were used to lend additional support into the
structural trends determined by computational analyses. The CD study was conducted in
aqueous media (H2O, phosphate buffered saline, PBS) to determine the influence of salt on
peptide conformation. Moreover, the CD spectra of the peptides were also collected in
DMSO, to support the NMR data. The CD curve for the parent peptide, Ac-DIYET-NH2 was
typical of a random coil or a disordered structure, characterized by the strong negative band
at 190 nm. At the 2 position, the [aza-Ile2], [aza-Ala2] and the [aza-Gly2]-residues exhibited
CD spectra that were respectively associated with random coils in water (Figure 3.6), a
combination of helical and turn geometries in phosphate buffer (Figure 3.7) and folded
conformations in DMSO (Figure 3.8). Thus, the solvent conditions were found to impact the
azapeptide folds, indicating the influence of solvent and aza substitutions at the i+1 position
on the peptide conformations. At the 3 position, the [aza-Tyr3], [aza-DOPA3] and [aza-Phe3]
modifications were found to exhibit CD spectra with characteristic positive bands near 215
nm and two negative ones near 230 and 190 nm. The observed CD traces are indicative of a
β-turn geometry, with some proportion of random coil due to the sharp negative minima
observed near 190 nm (Figure 3.9). The observed -turn geometry was also maintained for
the azapeptide dissolved in phosphate buffer (Figure 3.10), whereas peptide folds were
observed in DMSO (Figure 3.11). Thus, the insertion of aza-residues at the i+2 position were
found to stabilize a turn conformation about the peptide backbone geometry. Moving to the 4
position, [aza-Glu3], 2.42, displayed a CD spectrum in water, PBS and DMSO that failed to
stabilize a peptide turn conformation. These results were based on the large proportion of
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random coil observed in water and characterized by the negative minimum band at 190 nm
(Figures 3.12). In phosphate buffer, the azapeptide displayed a large positive band near 190
nm that are typically consistent with helical type structures (Figure 3.13). In DMSO, a poorly
folded peptide geometry indicated that the aza-Glu modification at the 4 position failed to
stabilize the peptide secondary structure (Figure 3.14).
The NMR spectrum of the parent pentapeptide Ac-DIYET-NH2, 2.28 was compared
to azapeptide, 2.36, in deuterated water and DMSO. In DMSO, the azapeptide displayed an
NMR spectrum that was indicative of a β-turn. This azapeptide secondary structure was
characterized by the disappearance of the Glu NH and down-field chemical shift of the Ile
NH (δ: 8.2 vs 7.6) when compared to the parent peptide (Figure 3.15 A and B, respectively).
This observation is consistent with the hydrogen bonding interaction found in between the
carbonyl group of the Asp residue at the i position and the amino group of the Glu residue at
the i+3 position to generate the turn conformation that is stabilized by the aza-Tyr residue at
the i+2 position. Moreover, 2D NOESY confirmed multiple NOE correlations that were
consistent with a folded azapeptide geometry that was absent within the parent peptide whose
protons appeared to be solvent exposed with fewer NOE correlations (Figure 3.16).
After the confirmation of the peptide structures, biology was next examined towards
the development of an azapeptide analog which may improve the inhibitory activity of the
Ac-DIYET-NH2 sequence towards the IRTK (Chapter 4).

5.1.2 BIOLOGICAL ACTIVITY OF AZAPEPTIDE ANALOGS
In Chapter 4 of this thesis, a preliminary study on the inhibitory activity of the
azapeptide Ac-DIazaYET-NH2 (2.36) in comparison with the native sequence Ac-DIYETNH2 (2.28) was performed by western blot. The phosphorylation activity of the recombinant
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IRTK domain (residues 1005-1310) was initially determined with the IRTK (200 ng/mL)
(Figure 4.5, lane 1), the IRTK (200 ng/mL) and ATP (1000 µM) (Figure 4.5, lane 2), and
with the IRTK (200 ng/mL), ATP (1000 µM) and insulin (200 ng/mL) (Figure 4.5, lane 3),
in a reaction buffer at pH 7.4, consisting of HEPES, NaCl, EDTA, MgCl2, MnCl2, DTT, and
phenylmethylsufonyl fluoride. The extent of the IRTK phosphorylation reactions was probed
with an anti-phospho-IRTK primary antibody and a secondary one conjugated with alkaline
phosphatase for detection. A band was observed when the IRTK was phosphorylated with
ATP (Figure 4.5, lane 2) and a more intense signal, albeit with a modest increase of ~10%
relative to the control IRTK + ATP sample was observed with additional insulin (Figure 4.5,
lane 3).
In this single dose (400 µM) experiment, minimal inhibitory activity (<10%) was detected
for the parent peptide, Ac-DIYET-NH2 (2.28), whereas, Ac-DIazaYET-NH2 (2.36) displayed
about 50% inhibition of the IRTK autophosphorylation (Figure 4.6). This result lends
supporting evidence that the β-turn conformation adopted by, Ac-DIazaYET-NH2 (2.36) may
contribute to IRTK binding affinity and inhibitory activity at the IRTK active site. A doseresponse (0 - 400 µM) study wiith Ac-DIazaYET-NH2 (2.36), maintained about 50%
inhibitory activity of the IRTK autophosphorylation at 400 µM, without a dose-response
correlation.
In sum, a new class of azapeptide inhibitors of the IRTK domain have been validated in
this thesis. The selected azapeptide, Ac-DIazaYET-NH2 (2.36), which demonstrated a stable
β-turn geometry resulted in a about 5-fold increase in IRTK inhibitory activity relative to the
parent pentapeptide (50 vs <10%). Thus, azapeptide inhibitors of the IRTK may form new
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leads in the development of potent and selective Tyr kinase binding ligands for anti-cancer
and related medicinal chemistry applications.
5.1.3 FUTURE WORK
The submonomer approach for azapeptide synthesis is especially useful in the production
of a library of structurally diverse azapeptides to further our SAR studies. As part of our
ongoing SAR studies, future work will be geared towards additional biology experiments that
will be used to evaluate the in-vitro IRTK phosphorylation inhibitory activity of the
azapeptide ligands. Moreover, mechanistic insights can also be gained by the azapeptides that
may function as valuable probes for elucidating their mechanisms of IRTK inhibitory
activity. This enzyme-based study will pave the way for cell-based assays, in which a
relevant tumor cell line model (eg. HepG2 cells) known to overexpress IRTK will be used to
determine the potential of the azapeptides to inhibit IRTK signaling activity in cancer. A
variety of molecular markers may be evaluated for this cell based assay, including IRTK
phosphorylation levels and a number of downstream substrates (i.e. IRS-1, c-Raf, Ras and
Sos) known to activate oncogenic signaling. Moreover, caspase activation and cell death
measurements may be used to evaluate the anti-cancer potential of the azapeptides. These
fruitful experiments will facilitate the selection of a lead azapeptide inhibitor that may be
screened in multiple cell types to validate efficacy and selectivity. A medicinal chemistry
approach may then be used to optimize the ‘drug-like’ properties of the azapeptide en route
towards the development of a potent and selective peptidomimetic therapeutic.

Page 112 of 172

5.2

PUBLICATIONS AND CONFERENCE PRESENTATIONS


Manuscript submitted for publication

1. Lathamol A. Kurian, Tammy A. Silva and David Sabatino - Submonomer Synthesis
of Azapeptide Ligands of the Insulin Receptor Tyrosine Kinase Domain.
Bioorganic and Medicinal Chemistry Letters 2014, asaps.



Poster Presentations

1. Lathamol A Kurian and David Sabatino. Submonomer Solid-Phase Synthesis of
Azapeptide Inhibitors of the Insulin Receptor Tyrosine Kinase. IBC 16th Annual
TIDES Conference, Providence, RI, May 12, 2014.

2. Lathamol A Kurian and David Sabatino Azapeptide Inhibitors of the Insulin
Receptor Tyrosine Kinase. AAPS Annual Meeting and Exposition, San Diego, CA.
Nov 2 - 6, 2014 (Poster accepted # AM-14-0439).

3. Stesha Joseph, Lathamol Kurian, Mariana Phillips, Ivonne Martinez, Brittany
Blackman҂, Christopher Parronchi, Megan Kelly, Michael Beaury, Constantine
Bitsaktsis, Allan Blake and David Sabatino, Synthesis, Characterization and
Biological Evaluation of Cancer-Targeting Peptides. NYAS, Chemical Biology
Discussion Year-End Symposium, New York, NY, June 3, 2014.

4. Stesha C. Joseph, Anthony Maina, Mariana Phillips, Lathamol A Kurian, Emily
Borland, Ivonne Martinez, and David Sabatino, Cancer-Targeting Peptides in

Page 113 of 172

Cancer Therapy. 17th Annual Petersheim Academic Symposium, Seton Hall
University, South Orange, NJ, April 23, 2013.

5. Stesha C. Joseph, Lathamol A Kurian, Leah R. Poland, Tammy A. Silva, and David
Sabatino, How do we make peptides in the lab? 16th Annual Petersheim Academic
Symposium, Seton Hall University.

Page 114 of 172

APPENDIX A

TABLE OF CONTENTS

Figure A1

RP-HPLC analysis of crude Ac-DIYazaET-NH2, 2.42.

118

Figure A2

ESI-LCMS analysis of crude Ac-DIYazaET-NH2, 2.42.

119

Figure A3

RP-HPLC analysis of pure Ac-DIYazaET-NH2, 2.42.

120

Figure A4

ESI-LCMS analysis of pure Ac-DIYazaET-NH2, 2.42.

121

Figure A5

RP-HPLC analysis of pure Ac-DIYazaET-NH2, 2.42.

122

Figure A6

ESI-LCMS analysis of pure Ac-DIYazaET-NH2, 2.42.

123

Figure A7

RP-HPLC analysis of crude Ac-DazaAYET-NH2, 2.37.

124

Figure A8

ESI-LCMS analysis of crude Ac-DazaAYET-NH2, 2.37.

125

Figure A9

RP-HPLC analysis of pure Ac-DazaAYET-NH2, 2.37.

126

Figure A10

ESI-LCMS analysis of pure Ac-DazaAYET-NH2, 2.37.

127

Figure A11

RP-HPLC analysis of pure Ac-DazaAYET-NH2, 2.37.

128

Figure A12

ESI-LCMS analysis of pure Ac-DazaAYET-NH2, 2.37.

129

Figure A13

RP-HPLC analysis of crude Ac-DazaGYET-NH2, 2.39.

130

Figure A14

ESI-LCMS analysis of crude Ac-DazaGYET-NH2, 2.39.

131

Figure A15

RP-HPLC analysis of pure Ac-DazaGYET-NH2, 2.39.

132

Figure A16

ESI-LCMS analysis of pure Ac-DazaGYET-NH2, 2.39.

133

Figure A17

RP-HPLC analysis of pure Ac-DazaGYET-NH2, 2.39.

134

Figure A18

ESI-LCMS analysis of pure Ac-DazaGYET-NH2, 2.39.

135

Figure A19

RP-HPLC analysis of crude Ac-DazaIYET-NH2, 2.38.

136

Figure A20

ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38.

137

Page 115 of 172

Figure A21

ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38.

138

Figure A22

ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38.

139

Figure A23

RP-HPLC analysis of pure Ac-DazaIYET-NH2, 2.38.

140

Figure A24

ESI-LCMS analysis of pure Ac-DazaIYET-NH2, 2.38.

141

Figure A25

RP-HPLC analysis of crude Ac-DIazaFET-NH2, 2.40.

142

Figure A26

ESI-LCMS analysis of crude Ac-DIazaFET-NH2, 2.40.

143

Figure A27

RP-HPLC analysis of crude Ac-DIazaFET-NH2, 2.40.

144

Figure A28

ESI-LCMS analysis of pure Ac-DIazaFET-NH2, 2.40.

145

Figure A29

ESI-LCMS analysis of pure Ac-DIazaFET-NH2, 2.40.

146

Figure A30

ESI-LCMS analysis of crude Ac-DIazaFET-NH2, 2.40.

147

Figure A31

RP-HPLC analysis of crude Ac-DIazaYET-NH2, 2.36.

148

Figure A32

ESI-LCMS analysis of crude Ac-DIazaYET-NH2, 2.36.

149

Figure A33

RP-HPLC analysis of pure Ac-DIazaYET-NH2, 2.36.

150

Figure A34

ESI-LCMS analysis of pure Ac-DIazaYET-NH2, 2.36.

151

Figure A35

RP-HPLC analysis of pure Ac-DIazaYET-NH2, 2.36.

152

Figure A36

RP-HPLC analysis of crude Ac-DIazaYET-NH2, 2.36.

153

Figure A37

RP-HPLC analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A38

RP-HPLC analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41.

155

Figure A39

RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A40

ESI-LCMS analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A41

RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A42

ESI-LCMS analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A43

RP-HPLC analysis of crude Ac-DIYET-NH2, 2.28.
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Figure A44

ESI-LCMS analysis of crude Ac-DIYET-NH2, 2.28.
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Figure A45

RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41.
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Figure A46

ESI-LCMS analysis of pure Ac-DIYET-NH2, 2.28.
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Figure A47

1

H NMR spectra of Ac-DIaza(DOPA)ET sequence, 2.41.
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Figure A48

1

H NMR spectra of Ac-DIYazaET sequence, 2.42.
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Figure A49

1

H NMR spectra of Ac-DazaIYET sequence, 2.38.
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Figure A50

1

H NMR spectra of Ac-DazaGYET sequence, 2.39.
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Figure A51

1

H NMR spectra of Ac-DazaAYET sequence, 2.37.
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Figure A52

1

H NMR spectra of Ac-DIYazaET sequence, 2.42.
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Figure A53

1

H NMR spectra of Ac-DIazaFET sequence, 2.40.
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Figure A54

1

H NMR spectra of Ac-DIazaYET sequence, 2.36.
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Figure A55

2D NOESY of Ac-DIYET-NH2, 2.28.
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172

2.42

Figure A1. RP-HPLC analysis of crude Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A2. ESI-LCMS analysis of crude Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A3. RP-HPLC analysis of pure Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A4. ESI-LCMS analysis of pure Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A5. RP-HPLC analysis of pure Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A6. ESI-LCMS analysis of pure Ac-DIYazaET-NH2, 2.42, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A7. RP-HPLC analysis of crude Ac-DazaAYET-NH2, 2.37, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A8. ESI-LCMS analysis of crude Ac-DazaAYET-NH2, 2.37, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A9. RP-HPLC analysis of pure Ac-DazaAYET-NH2, 2.37, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A10. ESI-LCMS analysis of pure Ac-DazaAYET-NH2, 2.37, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A11. RP-HPLC analysis of pure Ac-DazaAYET-NH2, 2.37, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A12. ESI-LCMS analysis of pure Ac-DazaAYET-NH2, 2.37, using a linear gradient
2-90% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A13. RP-HPLC analysis of crude Ac-DazaGYET-NH2, 2.39, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A14. ESI-LCMS analysis of crude Ac-DazaGYET-NH2, 2.39, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A15. RP-HPLC analysis of pure Ac-DazaGYET-NH2, 2.39, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A16. ESI-LCMS analysis of pure Ac-DazaGYET-NH2, 2.39, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A17. RP-HPLC analysis of pure Ac-DazaGYET-NH2, 2.39, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A18. ESI-LCMS analysis of pure Ac-DazaGYET-NH2, 2.39, using a linear gradient
2-90% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.

Page 135 of 172

Figure A19. RP-HPLC analysis of crude Ac-DazaIYET-NH2, 2.38, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A20. ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A21. ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A22. ESI-LCMS analysis of crude Ac-DazaIYET-NH2, 2.38, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A23. RP-HPLC analysis of pure Ac-DazaIYET-NH2, 2.38, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A24. ESI-LCMS analysis of pure Ac-DazaIYET-NH2, 2.38, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A25. RP-HPLC analysis of crude Ac-DIazaFET-NH2, 2.40, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A26. ESI-LCMS analysis of crude Ac-DIazaFET-NH2, 2.40, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A27. RP-HPLC analysis of crude Ac-DIazaFET-NH2, 2.40, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A28. ESI-LCMS analysis of pure Ac-DIazaFET-NH2, 2.40, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A29. ESI-LCMS analysis of pure Ac-DIazaFET-NH2, 2.40, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A30. ESI-LCMS analysis of crude Ac-DIazaFET-NH2, 2.40, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A31. RP-HPLC analysis of crude Ac-DIazaYET-NH2, 2.36, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A32. ESI-LCMS analysis of crude Ac-DIazaYET-NH2, 2.36, using a linear gradient
2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with negative mode of detection.
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Figure A33. RP-HPLC analysis of pure Ac-DIazaYET-NH2, 2.36, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A34. ESI-LCMS analysis of pure Ac-DIazaYET-NH2, 2.36, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A35. RP-HPLC analysis of pure Ac-DIazaYET-NH2, 2.36, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A36. RP-HPLC analysis of crude Ac-DIazaYET-NH2, 2.36, using a linear gradient 290% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A37. RP-HPLC analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with detection at 214 nm.
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Figure A38. RP-HPLC analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with positive mode of detection.
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Figure A39. RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with detection at 214 nm.
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Figure A40. ESI-LCMS analysis of crude Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with negative mode of detection.
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Figure A41. RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with detection at 214 nm.
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Figure A42. ESI-LCMS analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with negative mode of detection.
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2.28
Figure A43. RP-HPLC analysis of crude Ac-DIYET-NH2, 2.28, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with detection at 214 nm.
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Figure A44. ESI-LCMS analysis of crude Ac-DIYET-NH2, 2.28, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A45. RP-HPLC analysis of pure Ac-DIaza(DOPA)ET-NH2, 2.41, using a linear
gradient 2-90% CH3CN/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reversephase column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1
mL/min with detection at 214 nm.
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Figure A46. ESI-LCMS analysis of pure Ac-DIYET-NH2, 2.28, using a linear gradient 290% CH3OH/H2O (0.1% FA) over 15 min using a Symmetry Shield C18 reverse-phase
column (150 × 4.60 mm, 3.5 μm) set at a temperature of 25 °C at a flow rate of 1 mL/min
with positive mode of detection.
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Figure A47. 1H NMR spectra of Ac-DIaza(DOPA)ET sequence, 2.41, (2 mM) in DMSO-d6.
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2.42
Figure A48. 1H NMR spectra of Ac-DIYazaET sequence, 2.42, (2 mM) in DMSO-d6.
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Figure A49. 1H NMR spectra of Ac-DazaIYET sequence, 2.38, (2 mM) in DMSO-d6.

Page 166 of 172

Figure A50. 1H NMR spectra of Ac-DazaGYET sequence, 2.39, (2 mM) in DMSO-d6.
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Figure A51. 1H NMR spectra of Ac-DazaAYET sequence, 2.37, (2 mM) in DMSO-d6.
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2.42

Figure A52. 1H NMR spectra of Ac-DIYazaET sequence, 2.42, (2 mM) in DMSO-d6.
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Figure A53. 1H NMR spectra of Ac-DIazaFET sequence, 2.40, (2 mM) in DMSO-d6.
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Figure A54. 1H NMR spectra of Ac-DIazaYET sequence, 2.36, (2 mM) in DMSO-d6.
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Figure A55. 2D NOESY spectrum and conformational analysis of Ac-DIYET-NH2,
2.28, (2 mM) in DMSO-d6.
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